10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended March 31, 2023

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the transition period from              to              

Commission file numbers: 001-34465

SELECT MEDICAL HOLDINGS CORPORATION

(Exact name of Registrant as specified in its Charter)

Delaware	20-1764048
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification Number)

4714 Gettysburg Road, P.O. Box 2034

Mechanicsburg, PA 17055

(Address of Principal Executive Offices and Zip code)

(717) 972-1100

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	SEM	New York Stock Exchange
		(NYSE)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods as such Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes  ☒  No ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).   Yes ☒ No ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging Growth Company	☐

 If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐  No ☒

As of April 30, 2023, Select Medical Holdings Corporation had outstanding 127,126,909 shares of common stock.

Unless the context indicates otherwise, any reference in this report to “Holdings” refers to Select Medical Holdings Corporation and any reference to “Select” refers to Select Medical Corporation, the wholly owned operating subsidiary of Holdings, and any of Select’s subsidiaries. Any reference to “Concentra” refers to Concentra Group Holdings Parent, LLC (“Concentra Group Holdings Parent”) and its subsidiaries, including Concentra Inc. References to the “Company,” “we,” “us,” and “our” refer collectively to Holdings, Select, and Concentra.

1

TABLE OF CONTENTS

PART I	FINANCIAL INFORMATION	3
ITEM 1.	CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
	Condensed consolidated balance sheets	3
	Condensed consolidated statements of operations	4
	Condensed consolidated statements of comprehensive income	5
	Condensed consolidated statements of changes in equity and income	6
	Condensed consolidated statements of cash flows	7
	Notes to condensed consolidated financial statements	8
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	19
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	35
ITEM 4.	CONTROLS AND PROCEDURES	35
PART II	OTHER INFORMATION	36
ITEM 1.	LEGAL PROCEEDINGS	36
ITEM 1A.	RISK FACTORS	36
ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	36
ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	36
ITEM 4.	MINE SAFETY DISCLOSURES	36
ITEM 5.	OTHER INFORMATION	36
ITEM 6.	EXHIBITS	37
SIGNATURES

2

PART I: FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Select Medical Holdings Corporation

Condensed Consolidated Balance Sheets

(unaudited)

(in thousands, except share and per share amounts)

	December 31, 2022		March 31, 2023
ASSETS
Current Assets:
Cash and cash equivalents	$	97,906	$	83,703
Accounts receivable	941,312		997,274
Prepaid income taxes	31,868		16,893
Current portion of interest rate cap contract	74,857		72,127
Other current assets	125,370		143,736
Total Current Assets	1,271,313		1,313,733
Operating lease right-of-use assets	1,169,740		1,186,534
Property and equipment, net	1,001,440		987,283
Goodwill	3,484,200		3,484,594
Identifiable intangible assets, net	351,662		346,606
Interest rate cap contract, net of current portion	45,200		26,994
Other assets	341,738		353,992
Total Assets	$	7,665,293	$	7,699,736
LIABILITIES AND EQUITY
Current Liabilities:
Overdrafts	$	31,961	$	31,237
Current operating lease liabilities	236,784		239,713
Current portion of long-term debt and notes payable	44,351		113,894
Accounts payable	186,729		174,101
Accrued payroll	209,789		171,815
Accrued vacation	150,695		156,433
Accrued interest	29,837		10,241
Accrued other	264,525		274,654
Income taxes payable	480		13,618
Total Current Liabilities	1,155,151		1,185,706
Non-current operating lease liabilities	1,008,394		1,024,676
Long-term debt, net of current portion	3,835,211		3,766,838
Non-current deferred tax liability	169,793		163,024
Other non-current liabilities	106,137		106,652
Total Liabilities	6,274,686		6,246,896
Commitments and contingencies (Note 13)
Redeemable non-controlling interests	34,043		34,399
Stockholders’ Equity:
Common stock, $0.001 par value, 700,000,000 shares authorized, 127,173,871 and 127,176,279 shares issued and outstanding at 2022 and 2023, respectively	127		127
Capital in excess of par	452,183		462,185
Retained earnings	581,010		635,483
Accumulated other comprehensive income	88,602		72,654
Total Stockholders’ Equity	1,121,922		1,170,449
Non-controlling interests	234,642		247,992
Total Equity	1,356,564		1,418,441
Total Liabilities and Equity	$	7,665,293	$	7,699,736

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

Select Medical Holdings Corporation

Condensed Consolidated Statements of Operations

(unaudited)

(in thousands, except per share amounts)

	For the Three Months Ended March 31,
	2022		2023
Revenue	$	1,599,547	$	1,664,980
Costs and expenses:
Cost of services, exclusive of depreciation and amortization	1,407,010		1,418,819
General and administrative	37,513		42,279
Depreciation and amortization	51,039		52,425
Total costs and expenses	1,495,562		1,513,523
Income from operations	103,985		151,457
Other income and expense:
Equity in earnings of unconsolidated subsidiaries	5,397		8,556
Interest expense	(35,514)		(48,571)
Income before income taxes	73,868		111,442
Income tax expense	17,942		26,185
Net income	55,926		85,257
Less: Net income attributable to non-controlling interests	6,809		14,452
Net income attributable to Select Medical Holdings Corporation	$	49,117	$	70,805
Earnings per common share (Note 12):
Basic and diluted	$	0.37	$	0.56

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

Select Medical Holdings Corporation

Condensed Consolidated Statements of Comprehensive Income

(unaudited)

(in thousands)

	For the Three Months Ended March 31,
	2022		2023
Net income	$	55,926	$	85,257
Other comprehensive income (loss), net of tax:
Gain (loss) on interest rate cap contract	39,814		(2,696)
Reclassification adjustment for losses (gains) included in net income	39		(13,252)
Net change, net of tax benefit (expense) of $(13,284) and $5,175	39,853		(15,948)
Comprehensive income	95,779		69,309
Less: Comprehensive income attributable to non-controlling interests	6,809		14,452
Comprehensive income attributable to Select Medical Holdings Corporation	$	88,970	$	54,857

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

Select Medical Holdings Corporation

Condensed Consolidated Statements of Changes in Equity and Income

(unaudited)

(in thousands)

	For the Three Months Ended March 31, 2023
		Total Stockholders’ Equity
	Common Stock Issued	Common Stock Par Value		Capital in Excess of Par		Retained Earnings		Accumulated Other Comprehensive Income		Total Stockholders’ Equity		Non-controlling Interests		Total Equity
Balance at December 31, 2022	127,173	$	127	$	452,183	$	581,010	$	88,602	$	1,121,922	$	234,642	$	1,356,564
Net income attributable to Select Medical Holdings Corporation						70,805				70,805				70,805
Net income attributable to non-controlling interests										—		12,811		12,811
Cash dividends declared for common stockholders ($0.125 per share)						(15,897)				(15,897)				(15,897)
Issuance of restricted stock	3	0		0						—				—
Vesting of restricted stock				10,003						10,003				10,003
Issuance of non-controlling interests										—		2,731		2,731
Non-controlling interests acquired in business combination										—		3,877		3,877
Distributions to and purchases of non-controlling interests										—		(6,069)		(6,069)
Redemption value adjustment on non-controlling interests						(436)				(436)				(436)
Other comprehensive income								(15,948)		(15,948)				(15,948)
Other				(1)		1				—				—
Balance at March 31, 2023	127,176	$	127	$	462,185	$	635,483	$	72,654	$	1,170,449	$	247,992	$	1,418,441

	For the Three Months Ended March 31, 2022
		Total Stockholders’ Equity
	Common Stock Issued	Common Stock Par Value		Capital in Excess of Par		Retained Earnings		Accumulated Other Comprehensive Income		Total Stockholders’ Equity		Non-controlling Interests		Total Equity
Balance at December 31, 2021	133,884	$	134	$	504,314	$	593,251	$	12,282	$	1,109,981	$	215,921	$	1,325,902
Net income attributable to Select Medical Holdings Corporation						49,117				49,117				49,117
Net income attributable to non-controlling interests										—		4,891		4,891
Cash dividends declared for common stockholders ($0.125 per share)						(16,691)				(16,691)				(16,691)
Issuance of restricted stock	13	0		0						—				—
Vesting of restricted stock				8,288						8,288				8,288
Repurchase of common shares	(2,128)	(2)		(23,459)		(28,215)				(51,676)				(51,676)
Issuance of non-controlling interests				651						651		4,578		5,229
Non-controlling interests acquired in business combination, measurement period adjustment										—		12,463		12,463
Distributions to and purchases of non-controlling interests										—		(9,097)		(9,097)
Redemption value adjustment on non-controlling interests						(1,381)				(1,381)				(1,381)
Other comprehensive income								39,853		39,853				39,853
Other						(2)				(2)				(2)
Balance at March 31, 2022	131,769	$	132	$	489,794	$	596,079	$	52,135	$	1,138,140	$	228,756	$	1,366,896

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

Select Medical Holdings Corporation

Condensed Consolidated Statements of Cash Flows

(unaudited)

(in thousands)

	For the Three Months Ended March 31,
	2022		2023
Operating activities
Net income	$	55,926	$	85,257
Adjustments to reconcile net income to net cash provided by operating activities:
Distributions from unconsolidated subsidiaries	7,486		2,566
Depreciation and amortization	51,039		52,425
Provision for expected credit losses	94		429
Equity in earnings of unconsolidated subsidiaries	(5,397)		(8,556)
Gain on sale or disposal of assets	(23)		(7)
Stock compensation expense	8,823		10,181
Amortization of debt discount, premium and issuance costs	558		565
Deferred income taxes	420		(2,601)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	(52,225)		(55,397)
Other current assets	(1,819)		(11,742)
Other assets	2,686		3,659
Accounts payable	16,074		(4,564)
Accrued expenses	(14,377)		(20,775)
Government advances	(62,928)		—
Net cash provided by operating activities	6,337		51,440
Investing activities
Business combinations, net of cash acquired	(5,186)		(397)
Purchases of property, equipment, and other assets	(46,845)		(58,885)
Investment in businesses	(3,337)		(9,800)
Proceeds from sale of assets	37		20
Net cash used in investing activities	(55,331)		(69,062)
Financing activities
Borrowings on revolving facilities	280,000		225,000
Payments on revolving facilities	(100,000)		(210,000)
Borrowings of other debt	15,794		21,448
Principal payments on other debt	(9,188)		(11,170)
Dividends paid to common stockholders	(16,691)		(15,897)
Repurchase of common stock	(51,676)		—
Decrease in overdrafts	(7,608)		(724)
Proceeds from issuance of non-controlling interests	5,229		2,731
Distributions to and purchases of non-controlling interests	(10,295)		(7,969)
Net cash provided by financing activities	105,565		3,419
Net increase (decrease) in cash and cash equivalents	56,571		(14,203)
Cash and cash equivalents at beginning of period	74,310		97,906
Cash and cash equivalents at end of period	$	130,881	$	83,703
Supplemental information
Cash paid for interest, excluding amounts received of $17,828 under the interest rate cap contract for the three months ended March 31, 2023	$	53,517	$	84,531
Cash paid for taxes	923		336

The accompanying notes are an integral part of these condensed consolidated financial statements.

7

SELECT MEDICAL HOLDINGS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1.                  Basis of Presentation

The unaudited condensed consolidated financial statements of Select Medical Holdings Corporation (“Holdings”) include the accounts of its wholly owned subsidiary, Select Medical Corporation (“Select”). Holdings conducts substantially all of its business through Select and its subsidiaries. Holdings, Select, and Select’s subsidiaries are collectively referred to as the “Company.” The unaudited condensed consolidated financial statements of the Company as of March 31, 2023, and for the three month periods ended March 31, 2022 and 2023, have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim reporting and the accounting principles generally accepted in the United States of America (“GAAP”). Accordingly, certain information and disclosures required by GAAP, which are normally included in the notes to the consolidated financial statements, have been condensed or omitted pursuant to those rules and regulations, although the Company believes the disclosure is adequate to make the information presented not misleading. In the opinion of management, such information contains all adjustments, which are normal and recurring in nature, necessary for a fair statement of the financial position, results of operations and cash flow for such periods. All significant intercompany transactions and balances have been eliminated.

The results of operations for the three months ended March 31, 2023, are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2023. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2022, contained in the Company’s Annual Report on Form 10-K filed with the SEC on February 23, 2023.

2.    Accounting Policies

Recent Accounting Guidance Not Yet Adopted

In March 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-01, Leases (Topic 842): Common Control Arrangements, which requires companies to amortize leasehold improvements associated with related party leases under common control over the useful life of the leasehold improvement to the common control group. The ASU is effective for annual reporting periods beginning on or after December 15, 2023, however, early adoption is permitted. The ASU can either be applied prospectively or retrospectively.

The Company is currently evaluating this ASU, but does not expect it to have a material impact on its consolidated financial statements upon adoption. The Company plans to adopt the ASU using the prospective method as of January 1, 2024.

Recently Adopted Accounting Guidance

Reference Rate Reform

In December 2022, FASB issued ASU 2022-06, Reference Rate Reform (Topic 848), Deferral of the Sunset Date of Topic 848, which extended the relief provided under Topic 848 to contract modifications made and hedging relationships entered into on or before December 31, 2024. The FASB had previously issued ASU 2020-04, Reference Rate Reform (Topic 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting in March 2020, which provided temporary relief from some of the existing accounting rules governing contract modifications when the modification is related to the replacement of the London Interbank Offered Rate (“LIBOR”) or other reference rates discontinued as a result of reference rate reform.

For eligible contract modifications, the update generally allows an entity to account for and present modifications as an event that does not require contract remeasurement at the modification date or reassessment of a previous accounting determination. That is, the modified contract is accounted for as a continuation of the existing contract. For cash flow hedging relationships affected by reference rate reform, Topic 848 provides expedients that allow an entity to (i) change the reference rate of either the forecasted transaction or hedging instrument without requiring dedesignation of the hedging relationship; (ii) assert that changes to the hedged forecasted transaction will not impact whether it remains probable of occurring; and (iii) for the purposes of assessment of hedge effectiveness assume that the reference rate will not be replaced for the remainder of the hedging relationship if both the hedged forecasted transaction and hedging instrument are expected to be impacted by reference rate reform.

8

In March 2021, the Financial Conduct Authority announced that the intended cessation date of the one-, three-, six-, and 12-month tenors of USD LIBOR is June 30, 2023. Borrowings under the Company’s credit agreement bear interest, at the election of Select, based on LIBOR or an alternate base rate. The Company currently elects for its term loan borrowings to bear interest at a rate that is indexed to one-month LIBOR. Provisions within the credit agreement provide the Company with the ability to agree with JPMorgan Chase Bank, N.A., as administrative agent to the lenders, to replace LIBOR with a different reference rate in the event that LIBOR ceases to exist. The Company has not yet agreed upon a different reference rate with JPMorgan Chase Bank, N.A.

For the Company’s cash flow hedge, which mitigates the Company’s exposure to increases in the one-month LIBOR rate above 1.0% on $2.0 billion of principal outstanding under the term loan, the Company has elected to assert that the hedged forecasted transaction remains probable of occurring, regardless of a modification or expected modification that may replace one-month LIBOR with a different reference rate. The Company intends to modify the cash flow hedge’s contractual terms related to the replacement of the reference rate, as necessary, to align with the reference rate specified for the Company’s term loan. For the purpose of the assessment of hedge effectiveness, the Company assumes that the reference rate will not be replaced for the remainder of the hedging relationship, as outlined by Topic 848. The Company’s cash flow hedge is described further in Note 8 – Interest Rate Cap.

These updates have not had, and the Company does not expect them to have in future periods, a material impact on the Company's consolidated financial statements.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. Actual results could differ from those estimates.

3.     Credit Risk Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash balances and accounts receivable. The Company’s excess cash is held with large financial institutions. The Company grants unsecured credit to its patients, most of whom reside in the service area of the Company’s facilities and are insured under third-party payor agreements.

Because of the diversity in the Company’s non-governmental third-party payor base, as well as their geographic dispersion, accounts receivable due from the Medicare program represent the Company’s only significant concentration of credit risk. Approximately 19% and 20% of the Company’s accounts receivable is due from Medicare at December 31, 2022 and March 31, 2023, respectively.

4.     Redeemable Non-Controlling Interests

The ownership interests held by outside parties in subsidiaries, which include limited liability companies and limited partnerships, controlled by the Company are classified as non-controlling interests. Some of the Company’s non-controlling ownership interests consist of outside parties that have certain redemption rights that, if exercised, require the Company to purchase the parties’ ownership interests. These interests are classified and reported as redeemable non-controlling interests and have been adjusted to their approximate redemption values, after the attribution of net income or loss.

The changes in redeemable non-controlling interests are as follows:

	Three Months Ended March 31,
	2022		2023
	(in thousands)
Balance as of January 1	$	39,033	$	34,043
Net income attributable to redeemable non-controlling interests	1,918		1,641
Distributions to redeemable non-controlling interests	(1,198)		(1,900)
Redemption value adjustment on redeemable non-controlling interests	1,381		436
Other	536		179
Balance as of March 31	$	41,670	$	34,399

9

5.     Variable Interest Entities

Certain states prohibit the “corporate practice of medicine,” which restricts the Company from owning medical practices which directly employ physicians or therapists and from exercising control over medical decisions by physicians and therapists. In these states, the Company enters into long-term management agreements with medical practices that are owned by licensed physicians or therapists, which, in turn, employ or contract with physicians or therapists who provide professional medical services. The management agreements provide for the Company to direct the transfer of ownership of the medical practices. Based on the provisions of the management agreements, the medical practices are variable interest entities for which the Company is the primary beneficiary.

As of December 31, 2022, and March 31, 2023, the total assets of the Company’s variable interest entities were $232.1 million and $254.1 million, respectively, and are principally comprised of accounts receivable. As of December 31, 2022, and March 31, 2023, the total liabilities of the Company’s variable interest entities were $78.8 million and $82.2 million, respectively, and are principally comprised of accounts payable and accrued expenses. These variable interest entities have obligations payable for services received under their management agreements with the Company of $158.3 million and $178.4 million as of December 31, 2022, and March 31, 2023, respectively. These intercompany balances are eliminated in consolidation.

6.     Leases

The Company has operating and finance leases for its facilities. The Company leases its corporate office space from related parties.

The Company’s total lease cost is as follows:

	Three Months Ended March 31, 2022						Three Months Ended March 31, 2023
	Unrelated Parties		Related Parties		Total		Unrelated Parties		Related Parties		Total
	(in thousands)
Operating lease cost	$	73,962	$	1,809	$	75,771	$	76,632	$	1,834	$	78,466
Finance lease cost:
Amortization of right-of-use assets	347		—		347		394		—		394
Interest on lease liabilities	340		—		340		320		—		320
Short-term lease cost	35		—		35		—		—		—
Variable lease cost	13,655		39		13,694		15,761		84		15,845
Sublease income	(1,966)		—		(1,966)		(1,678)		—		(1,678)
Total lease cost	$	86,373	$	1,848	$	88,221	$	91,429	$	1,918	$	93,347

10

7.     Long-Term Debt and Notes Payable

As of March 31, 2023, the Company’s long-term debt and notes payable are as follows:

	Principal Outstanding		Unamortized Premium (Discount)		Unamortized Issuance Costs		Carrying Value		Fair Value
	(in thousands)
6.250% senior notes	$	1,225,000	$	20,065	$	(10,206)	$	1,234,859	$	1,188,250
Credit facilities:
Revolving facility	460,000		—		—		460,000		458,275
Term loan	2,103,437		(3,881)		(4,230)		2,095,326		2,095,549
Other debt, including finance leases	90,664		—		(117)		90,547		90,547
Total debt	$	3,879,101	$	16,184	$	(14,553)	$	3,880,732	$	3,832,621

Principal maturities of the Company’s long-term debt and notes payable are approximately as follows:

	2023		2024		2025		2026		2027		Thereafter		Total
	(in thousands)
6.250% senior notes	$	—	$	—	$	—	$	1,225,000	$	—	$	—	$	1,225,000
Credit facilities:
Revolving facility	—		84,923		375,077		—		—		—		460,000
Term loan	4,757		11,150		2,087,530		—		—		—		2,103,437
Other debt, including finance leases	19,928		56,356		1,408		1,308		823		10,841		90,664
Total debt	$	24,685	$	152,429	$	2,464,015	$	1,226,308	$	823	$	10,841	$	3,879,101

As of December 31, 2022, the Company’s long-term debt and notes payable are as follows:

	Principal Outstanding		Unamortized Premium (Discount)		Unamortized Issuance Costs		Carrying Value		Fair Value
	(in thousands)
6.250% senior notes	$	1,225,000	$	21,555	$	(10,948)	$	1,235,607	$	1,163,689
Credit facilities:
Revolving facility	445,000		—		—		445,000		443,331
Term loan	2,103,437		(4,376)		(4,771)		2,094,290		2,056,110
Other debt, including finance leases	104,800		—		(135)		104,665		104,665
Total debt	$	3,878,237	$	17,179	$	(15,854)	$	3,879,562	$	3,767,795

Select Credit Facilities

On February 21, 2023, Select entered into Amendment No. 6 to its senior secured credit agreement (the “Select credit agreement”). Amendment No. 6 extended the maturity date on $530.0 million of the total borrowing capacity of $650.0 million under its revolving credit facility (the “Select revolving facility”) to March 6, 2025; however, in the event the Company’s term loan is not refinanced by January 3, 2025, the maturity date for those revolving borrowings will be January 3, 2025.

11

8.     Interest Rate Cap

The Company is subject to market risk exposure arising from changes in interest rates on its term loan, which bears interest at a rate that is indexed to one-month LIBOR. The Company’s objective in using an interest rate derivative is to mitigate its exposure to increases in interest rates. The interest rate cap limits the Company’s exposure to increases in the one-month LIBOR rate to 1.0% on $2.0 billion of principal outstanding under the term loan, as the interest rate cap provides for payments from the counterparty when interest rates rise above 1.0%. The interest rate cap has a $2.0 billion notional amount and is effective through September 30, 2024. The Company will pay a monthly premium for the interest rate cap over the term of the agreement. The annual premium is equal to 0.0916% of the notional amount, or approximately $1.8 million.

The interest rate cap has been designated as a cash flow hedge and is highly effective at offsetting the changes in cash outflows when one-month LIBOR exceeds 1.0%. Changes in the fair value of the interest rate cap, net of tax, are recognized in other comprehensive income and are reclassified out of accumulated other comprehensive income and into interest expense when the hedged interest obligations affect earnings.

The following table outlines the changes in accumulated other comprehensive income (loss), net of tax, during the periods presented:

	Three Months Ended March 31,
	2022		2023
	(in thousands)
Balance as of January 1	$	12,282	$	88,602
Gain (loss) on interest rate cap cash flow hedge	39,814		(2,696)
Amounts reclassified from accumulated other comprehensive income	39		(13,252)
Balance as of March 31	$	52,135	$	72,654

The effects on net income of amounts reclassified from accumulated other comprehensive income are as follows:

	Three Months Ended March 31,
Statement of Operations	2022		2023
	(in thousands)
Gains (losses) included in interest expense	$	(51)	$	17,552
Income tax benefit (expense)	12		(4,300)
Amounts reclassified from accumulated other comprehensive income	$	(39)	$	13,252

The Company expects that approximately $71.1 million of estimated pre-tax gains will be reclassified from accumulated other comprehensive income into interest expense within the next twelve months.

Refer to Note 9 – Fair Value of Financial Instruments for information on the fair value of the Company’s interest rate cap contract and its balance sheet classification.

12

9.     Fair Value of Financial Instruments

Financial instruments which are measured at fair value, or for which a fair value is disclosed, are classified in the fair value hierarchy, as outlined below, on the basis of the observability of the inputs used in the fair value measurement:

•Level 1 – inputs are based upon quoted prices for identical instruments in active markets.

•Level 2 – inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data.

•Level 3 – inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the instrument.

The Company’s interest rate cap contract is recorded at its fair value in the condensed consolidated balance sheets on a recurring basis. The fair value of the interest rate cap contract is based upon a model-derived valuation using observable market inputs, such as interest rates and interest rate volatility, and the strike price.

Financial Instrument	Balance Sheet Classification	Level	December 31, 2022		March 31, 2023
Asset:			(in thousands)
Interest rate cap contract, current portion	Current portion of interest rate cap contract	Level 2	$	74,857	$	72,127
Interest rate cap contract, non-current portion	Interest rate cap contract, net of current portion	Level 2	45,200		26,994

The Company does not measure its indebtedness at fair value in its condensed consolidated balance sheets. The fair value of the credit facilities is based on quoted market prices for this debt in the syndicated loan market. The fair value of the senior notes is based on quoted market prices. The carrying value of the Company’s other debt, as disclosed in Note 7 – Long-Term Debt and Notes Payable, approximates fair value.

		December 31, 2022				March 31, 2023
Financial Instrument	Level	Carrying Value		Fair Value		Carrying Value		Fair Value
		(in thousands)
6.250% senior notes	Level 2	$	1,235,607	$	1,163,689	$	1,234,859	$	1,188,250
Credit facilities:
Revolving facility	Level 2	445,000		443,331		460,000		458,275
Term loan	Level 2	2,094,290		2,056,110		2,095,326		2,095,549

The Company’s other financial instruments, which primarily consist of cash and cash equivalents, accounts receivable, and accounts payable, approximate fair value because of the short-term maturities of these instruments.

13

10.     Segment Information

The Company’s reportable segments consist of the critical illness recovery hospital segment, rehabilitation hospital segment, outpatient rehabilitation segment, and Concentra segment. Other activities include the Company’s corporate shared services, certain investments, and employee leasing services with non-consolidating subsidiaries.

The Company evaluates the performance of its segments based on Adjusted EBITDA. Adjusted EBITDA is defined as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries. The Company has provided additional information regarding its reportable segments, such as total assets, which contributes to the understanding of the Company and provides useful information to the users of the consolidated financial statements.

The following tables summarize selected financial data for the Company’s reportable segments.

	Three Months Ended March 31,
	2022		2023
	(in thousands)
Revenue:
Critical illness recovery hospital	$	601,755	$	593,926
Rehabilitation hospital	220,634		231,462
Outpatient rehabilitation	271,940		295,903
Concentra	423,423		456,298
Other	81,795		87,391
Total Company	$	1,599,547	$	1,664,980
Adjusted EBITDA:
Critical illness recovery hospital	$	35,967	$	76,773
Rehabilitation hospital	42,379		47,216
Outpatient rehabilitation	26,596		30,199
Concentra	89,469		93,748
Other	(30,564)		(33,873)
Total Company	$	163,847	$	214,063
Total assets:
Critical illness recovery hospital	$	2,367,490	$	2,507,265
Rehabilitation hospital	1,187,118		1,203,069
Outpatient rehabilitation	1,350,374		1,397,823
Concentra	2,339,940		2,300,632
Other	291,022		290,947
Total Company	$	7,535,944	$	7,699,736
Purchases of property, equipment, and other assets:
Critical illness recovery hospital	$	19,569	$	23,658
Rehabilitation hospital	6,274		8,582
Outpatient rehabilitation	9,414		9,932
Concentra	10,240		14,400
Other	1,348		2,313
Total Company	$	46,845	$	58,885

14

A reconciliation of Adjusted EBITDA to income before income taxes is as follows:

	Three Months Ended March 31, 2022
	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra		Other		Total
	(in thousands)
Adjusted EBITDA	$	35,967	$	42,379	$	26,596	$	89,469	$	(30,564)
Depreciation and amortization	(14,618)		(6,802)		(8,029)		(18,812)		(2,778)
Stock compensation expense	—		—		—		(535)		(8,288)
Income (loss) from operations	$	21,349	$	35,577	$	18,567	$	70,122	$	(41,630)	$	103,985
Equity in earnings of unconsolidated subsidiaries											5,397
Interest expense											(35,514)
Income before income taxes											$	73,868

	Three Months Ended March 31, 2023
	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra		Other		Total
	(in thousands)
Adjusted EBITDA	$	76,773	$	47,216	$	30,199	$	93,748	$	(33,873)
Depreciation and amortization	(16,637)		(6,888)		(8,457)		(18,310)		(2,133)
Stock compensation expense	—		—		—		(178)		(10,003)
Income (loss) from operations	$	60,136	$	40,328	$	21,742	$	75,260	$	(46,009)	$	151,457
Equity in earnings of unconsolidated subsidiaries											8,556
Interest expense											(48,571)
Income before income taxes											$	111,442

11.     Revenue from Contracts with Customers

The following tables disaggregate the Company’s revenue for the three months ended March 31, 2022 and 2023:

	Three Months Ended March 31, 2022
	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra		Other		Total
	(in thousands)
Patient service revenue:
Medicare	$	218,987	$	103,021	$	41,904	$	177	$	—	$	364,089
Non-Medicare	380,986		107,142		214,113		422,046		—		1,124,287
Total patient services revenues	599,973		210,163		256,017		422,223		—		1,488,376
Other revenue	1,782		10,471		15,923		1,200		81,795		111,171
Total revenue	$	601,755	$	220,634	$	271,940	$	423,423	$	81,795	$	1,599,547

	Three Months Ended March 31, 2023
	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra		Other		Total
	(in thousands)
Patient service revenue:
Medicare	$	229,383	$	110,055	$	45,801	$	243	$	—	$	385,482
Non-Medicare	363,305		109,925		231,985		454,598		—		1,159,813
Total patient services revenues	592,688		219,980		277,786		454,841		—		1,545,295
Other revenue	1,238		11,482		18,117		1,457		87,391		119,685
Total revenue	$	593,926	$	231,462	$	295,903	$	456,298	$	87,391	$	1,664,980

15

12.    Earnings per Share

The Company’s capital structure includes common stock and unvested restricted stock awards. To compute earnings per share (“EPS”), the Company applies the two-class method because the Company’s unvested restricted stock awards are participating securities which are entitled to participate equally with the Company’s common stock in undistributed earnings. Application of the Company’s two-class method is as follows:

(i)Net income attributable to the Company is reduced by the amount of dividends declared and by the contractual amount of dividends that must be paid for the current period for each class of stock. There were no contractual dividends paid for the three months ended March 31, 2022 and 2023.

(ii)The remaining undistributed net income of the Company is then equally allocated to its common stock and unvested restricted stock awards, as if all of the earnings for the period had been distributed. The total net income allocated to each security is determined by adding both distributed and undistributed net income for the period.

(iii)The net income allocated to each security is then divided by the weighted average number of outstanding shares for the period to determine the EPS for each security considered in the two-class method.

The following table sets forth the net income attributable to the Company, its common shares outstanding, and its participating securities outstanding.

		Basic and Diluted EPS
		Three Months Ended March 31,
		2022		2023
	(in thousands)
Net income		$	55,926	$	85,257
Less: net income attributable to non-controlling interests		6,809		14,452
Net income attributable to the Company		49,117		70,805
Less: Distributed and undistributed income attributable to participating securities		1,643		2,573
Distributed and undistributed income attributable to common shares		$	47,474	$	68,232

The following tables set forth the computation of EPS under the two-class method:

	Three Months Ended March 31,
	2022					2023
	Net Income Allocation		Shares(1)	Basic and Diluted EPS		Net Income Allocation		Shares(1)	Basic and Diluted EPS
	(in thousands, except for per share amounts)
Common shares	$	47,474	129,010	$	0.37	$	68,232	122,553	$	0.56
Participating securities	1,643		4,464	$	0.37	2,573		4,622	$	0.56
Total Company	$	49,117				$	70,805

_______________________________________________________________________________

(1)    Represents the weighted average share count outstanding during the period.

16

13.    Commitments and Contingencies

Litigation

The Company is a party to various legal actions, proceedings, and claims (some of which are not insured), and regulatory and other governmental audits and investigations in the ordinary course of its business. The Company cannot predict the ultimate outcome of pending litigation, proceedings, and regulatory and other governmental audits and investigations. These matters could potentially subject the Company to sanctions, damages, recoupments, fines, and other penalties. The Department of Justice, Centers for Medicare & Medicaid Services (“CMS”), or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company’s businesses in the future that may, either individually or in the aggregate, have a material adverse effect on the Company’s business, financial position, results of operations, and liquidity.

To address claims arising out of the Company’s operations, the Company maintains professional malpractice liability insurance and general liability insurance coverages through a number of different programs that are dependent upon such factors as the state where the Company is operating and whether the operations are wholly owned or are operated through a joint venture. For the Company’s wholly owned hospital and outpatient clinic operations, the Company currently maintains insurance coverages under a combination of policies with a total annual aggregate limit of up to $37.0 million for professional malpractice liability insurance and $40.0 million for general liability insurance. For the Company’s Concentra center operations, the Company currently maintains insurance coverages under a combination of policies with a total annual aggregate limit of up to $19.0 million for professional malpractice liability insurance and $19.0 million for general liability insurance. The Company’s insurance for the professional liability coverage is written on a “claims-made” basis, and its commercial general liability coverage is maintained on an “occurrence” basis. These coverages apply after a self-insured retention limit is exceeded. For the Company’s joint venture operations, the Company has designed a separate insurance program that responds to the risks of specific joint ventures. Most of the Company’s joint ventures are insured under a master program with an annual aggregate limit of up to $80.0 million, subject to a sublimit aggregate ranging from $23.0 million to $33.0 million for most joint ventures. The policies are generally written on a “claims-made” basis. Each of these programs has either a deductible or self-insured retention limit. The Company also maintains additional types of liability insurance covering claims which, due to their nature or amount, are not covered by or not fully covered by the Company’s professional and general liability insurance policies. These insurance policies also do not generally cover punitive damages and are subject to various deductibles and policy limits. The Company reviews its insurance program annually and may make adjustments to the amount of insurance coverage and self-insured retentions in future years. Significant legal actions, as well as the cost and possible lack of available insurance, could subject the Company to substantial uninsured liabilities. In the Company’s opinion, the outcome of these actions, individually or in the aggregate, will not have a material adverse effect on its financial position, results of operations, or cash flows.

Healthcare providers are subject to lawsuits under the qui tam provisions of the federal False Claims Act. Qui tam lawsuits typically remain under seal (hence, usually unknown to the defendant) for some time while the government decides whether or not to intervene on behalf of a private qui tam plaintiff (known as a relator) and take the lead in the litigation. These lawsuits can involve significant monetary damages and penalties and award bounties to private plaintiffs who successfully bring the suits. The Company is and has been a defendant in these cases in the past, and may be named as a defendant in similar cases from time to time in the future.

Oklahoma City Subpoena. On August 24, 2020, the Company and Select Specialty Hospital – Oklahoma City, Inc. (“SSH–Oklahoma City”) received Civil Investigative Demands (“CIDs”) from the U.S. Attorney’s Office for the Western District of Oklahoma seeking responses to interrogatories and the production of various documents principally relating to the documentation, billing and reviews of medical services furnished to patients at SSH-Oklahoma City. The Company understands that the investigation arose from a qui tam lawsuit alleging billing fraud related to charges for respiratory therapy services at SSH-Oklahoma City and Select Specialty Hospital - Wichita, Inc. The Company has produced documents in response to the CIDs and is fully cooperating with this investigation. At this time, the Company is unable to predict the timing and outcome of this matter.

17

Physical Therapy Billing. On October 7, 2021, the Company received a letter from a Trial Attorney at the U.S. Department of Justice, Civil Division, Commercial Litigation Branch, Fraud Section (“DOJ”) stating that the DOJ, in conjunction with the U.S. Department of Health and Human Services (“HHS”), is investigating the Company in connection with potential violations of the False Claims Act, 31 U.S.C. § 3729, et seq. The letter specified that the investigation relates to the Company’s billing for physical therapy services, and indicated that the DOJ would be requesting certain records from the Company. In 2021, the DOJ requested, and the Company furnished, records relating to six of the Company’s outpatient therapy clinics in Florida. In 2022, the DOJ requested certain data relating to all of the Company’s outpatient therapy clinics nationwide, and sought information about the Company’s ability to produce additional data relating to the physical therapy services furnished by the Company’s outpatient therapy clinics and Concentra. The Company continues to produce data and other documents requested by the DOJ and is fully cooperating on this investigation. At this time, the Company is unable to predict the timing and outcome of this matter.

14.     Subsequent Event

On May 3, 2023, the Company’s Board of Directors declared a cash dividend of $0.125 per share. The dividend will be payable on or about May 31, 2023, to stockholders of record as of the close of business on May 18, 2023.

18

ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read this discussion together with our unaudited condensed consolidated financial statements and accompanying notes.

Forward-Looking Statements

This report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws. Statements that are not historical facts, including statements about our beliefs and expectations, are forward-looking statements. Forward-looking statements include statements preceded by, followed by or that include the words “may,” “could,” “would,” “should,” “believe,” “expect,” “anticipate,” “plan,” “target,” “estimate,” “project,” “intend,” and similar expressions. These statements include, among others, statements regarding our expected business outlook, anticipated financial and operating results, including the potential impact of the COVID-19 pandemic on those financial and operating results, our business strategy and means to implement our strategy, our objectives, the amount and timing of capital expenditures, the likelihood of our success in expanding our business, financing plans, budgets, working capital needs, and sources of liquidity.

Forward-looking statements are only predictions and are not guarantees of performance. These statements are based on our management’s beliefs and assumptions, which in turn are based on currently available information. Important assumptions relating to the forward-looking statements include, among others, assumptions regarding our services, the expansion of our services, competitive conditions, and general economic conditions. These assumptions could prove inaccurate. Forward-looking statements also involve known and unknown risks and uncertainties, which could cause actual results to differ materially from those contained in any forward-looking statement. Many of these factors are beyond our ability to control or predict. Such factors include, but are not limited to, the following:

•adverse economic conditions including an inflationary environment could cause us to continue to experience increases in the prices of labor and other costs of doing business resulting in a negative impact on our business, operating results, cash flows, and financial condition;

•shortages in qualified nurses, therapists, physicians, or other licensed providers, and/or the inability to attract or retain qualified healthcare professionals could limit our ability to staff our facilities;

•shortages in qualified health professionals could cause us to increase our dependence on contract labor, increase our efforts to recruit and train new employees, and expand upon our initiatives to retain existing staff, which could increase our operating costs significantly;

•the continuing effects of the COVID-19 pandemic including, but not limited to, the prolonged disruption to the global financial markets, increased operational costs due to recessionary pressures and labor costs, additional measures taken by government authorities and the private sector to limit the spread of COVID-19, and further legislative and regulatory actions which impact healthcare providers, including actions that may impact the Medicare program;

•changes in government reimbursement for our services and/or new payment policies may result in a reduction in revenue, an increase in costs, and a reduction in profitability;

•the failure of our Medicare-certified long term care hospitals or inpatient rehabilitation facilities to maintain their Medicare certifications may cause our revenue and profitability to decline;

•the failure of our Medicare-certified long term care hospitals and inpatient rehabilitation facilities operated as “hospitals within hospitals” to qualify as hospitals separate from their host hospitals may cause our revenue and profitability to decline;

•a government investigation or assertion that we have violated applicable regulations may result in sanctions or reputational harm and increased costs;

•acquisitions or joint ventures may prove difficult or unsuccessful, use significant resources, or expose us to unforeseen liabilities;

•our plans and expectations related to our acquisitions and our ability to realize anticipated synergies;

•private third-party payors for our services may adopt payment policies that could limit our future revenue and profitability;

•the failure to maintain established relationships with the physicians in the areas we serve could reduce our revenue and profitability;

19

•competition may limit our ability to grow and result in a decrease in our revenue and profitability;

•the loss of key members of our management team could significantly disrupt our operations;

•the effect of claims asserted against us could subject us to substantial uninsured liabilities;

•a security breach of our or our third-party vendors’ information technology systems may subject us to potential legal and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 or the Health Information Technology for Economic and Clinical Health Act; and

•other factors discussed from time to time in our filings with the SEC, including factors discussed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022.

Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements, whether as a result of any new information, future events, or otherwise. You should not place undue reliance on our forward-looking statements. Although we believe that the expectations reflected in forward-looking statements are reasonable, we cannot guarantee future results or performance.

Investors should also be aware that while we do, from time to time, communicate with securities analysts, it is against our policy to disclose to securities analysts any material non-public information or other confidential commercial information. Accordingly, stockholders should not assume that we agree with any statement or report issued by any securities analyst irrespective of the content of the statement or report. Thus, to the extent that reports issued by securities analysts contain any projections, forecasts or opinions, such reports are not the responsibility of the Company.

Overview

 We began operations in 1997 and, based on number of facilities, are one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. As of March 31, 2023, we had operations in 46 states and the District of Columbia. We operated 105 critical illness recovery hospitals in 28 states, 32 rehabilitation hospitals in 12 states, 1,936 outpatient rehabilitation clinics in 39 states and the District of Columbia, 539 occupational health centers in 41 states, and 140 onsite clinics at employer worksites.

Our reportable segments include the critical illness recovery hospital segment, the rehabilitation hospital segment, the outpatient rehabilitation segment, and the Concentra segment. We had revenue of $1,665.0 million for the three months ended March 31, 2023. Of this total, we earned approximately 36% of our revenue from our critical illness recovery hospital segment, approximately 14% from our rehabilitation hospital segment, approximately 18% from our outpatient rehabilitation segment, and approximately 27% from our Concentra segment. Our critical illness recovery hospital segment consists of hospitals designed to serve the needs of patients recovering from critical illnesses, often with complex medical needs, and our rehabilitation hospital segment consists of hospitals designed to serve patients that require intensive physical rehabilitation care. Patients are typically admitted to our critical illness recovery hospitals and rehabilitation hospitals from general acute care hospitals. Our outpatient rehabilitation segment consists of clinics that provide physical, occupational, and speech rehabilitation services. Our Concentra segment consists of occupational health centers that provide workers’ compensation injury care, physical therapy, and consumer health services as well as onsite clinics located at employer worksites that deliver occupational medicine services.

20

Non-GAAP Measure

We believe that the presentation of Adjusted EBITDA, as defined below, is important to investors because Adjusted EBITDA is commonly used as an analytical indicator of performance by investors within the healthcare industry. Adjusted EBITDA is used by management to evaluate financial performance and determine resource allocation for each of our segments. Adjusted EBITDA is not a measure of financial performance under GAAP. Items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Adjusted EBITDA should not be considered in isolation or as an alternative to, or substitute for, net income, income from operations, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying definitions, Adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies.

We define Adjusted EBITDA as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries. We will refer to Adjusted EBITDA throughout the remainder of Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following table reconciles net income and income from operations to Adjusted EBITDA and should be referenced when we discuss Adjusted EBITDA:

		Three Months Ended March 31,
		2022		2023
	(in thousands)
Net income		$	55,926	$	85,257
Income tax expense		17,942		26,185
Interest expense		35,514		48,571
Equity in earnings of unconsolidated subsidiaries		(5,397)		(8,556)
Income from operations		103,985		151,457
Stock compensation expense:
Included in general and administrative		6,949		8,405
Included in cost of services		1,874		1,776
Depreciation and amortization		51,039		52,425
Adjusted EBITDA		$	163,847	$	214,063

Other Significant Events

Dividend Payment

On February 16, 2023, our Board of Directors declared a cash dividend of $0.125 per share. On March 15, 2023, cash dividends totaling $15.9 million were paid.

Financing Transaction

On February 21, 2023, Select entered into Amendment No. 6 to the Select credit agreement. Amendment No. 6 extended the maturity date on $530.0 million of the total borrowing capacity of $650.0 million under the Select revolving facility to March 6, 2025; however, in the event the Company’s term loan is not refinanced by January 3, 2025, the maturity date for those revolving borrowings will be January 3, 2025.

21

Summary Financial Results

Three Months Ended March 31, 2023

The following tables reconcile our segment performance measures to our consolidated operating results:

	Three Months Ended March 31, 2023
	Critical Illness Recovery Hospital			Rehabilitation Hospital			Outpatient Rehabilitation			Concentra			Other		Total
	(in thousands)
Revenue	$	593,926		$	231,462		$	295,903		$	456,298		$	87,391	$	1,664,980
Operating expenses	(517,153)			(184,246)			(265,704)			(362,728)			(131,267)		(1,461,098)
Depreciation and amortization	(16,637)			(6,888)			(8,457)			(18,310)			(2,133)		(52,425)
Income (loss) from operations	$	60,136		$	40,328		$	21,742		$	75,260		$	(46,009)	$	151,457
Depreciation and amortization	16,637			6,888			8,457			18,310			2,133		52,425
Stock compensation expense	—			—			—			178			10,003		10,181
Adjusted EBITDA	$	76,773		$	47,216		$	30,199		$	93,748		$	(33,873)	$	214,063
Adjusted EBITDA margin	12.9		%	20.4		%	10.2		%	20.5		%	N/M		12.9		%

	Three Months Ended March 31, 2022
	Critical Illness Recovery Hospital			Rehabilitation Hospital			Outpatient Rehabilitation			Concentra			Other		Total
	(in thousands)
Revenue	$	601,755		$	220,634		$	271,940		$	423,423		$	81,795	$	1,599,547
Operating expenses	(565,788)			(178,255)			(245,344)			(334,489)			(120,647)		(1,444,523)
Depreciation and amortization	(14,618)			(6,802)			(8,029)			(18,812)			(2,778)		(51,039)
Income (loss) from operations	$	21,349		$	35,577		$	18,567		$	70,122		$	(41,630)	$	103,985
Depreciation and amortization	14,618			6,802			8,029			18,812			2,778		51,039
Stock compensation expense	—			—			—			535			8,288		8,823
Adjusted EBITDA	$	35,967		$	42,379		$	26,596		$	89,469		$	(30,564)	$	163,847
Adjusted EBITDA margin	6.0		%	19.2		%	9.8		%	21.1		%	N/M		10.2		%

Net income was $85.3 million for the three months ended March 31, 2023, compared to $55.9 million for the three months ended March 31, 2022.

The following table summarizes the changes in our segment performance measures for the three months ended March 31, 2023, compared to the three months ended March 31, 2022:

	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra		Other		Total
Change in revenue	(1.3)	%	4.9	%	8.8	%	7.8	%	6.8	%	4.1	%
Change in income from operations	181.7	%	13.4	%	17.1	%	7.3	%	N/M		45.7	%
Change in Adjusted EBITDA	113.5	%	11.4	%	13.5	%	4.8	%	N/M		30.6	%

_______________________________________________________________________________

N/M —     Not meaningful.

22

Regulatory Changes

Our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on February 23, 2023, contains a detailed discussion of the regulations that affect our business in Part I — Business — Government Regulations. The following is a discussion of some of the more significant healthcare regulatory changes that have affected our financial performance in the periods covered by this report, or are likely to affect our financial performance and financial condition in the future. The information below should be read in conjunction with the more detailed discussion of regulations contained in our Form 10-K.

Medicare Reimbursement

The Medicare program reimburses healthcare providers for services furnished to Medicare beneficiaries, which are generally persons age 65 and older, those who are chronically disabled, and those suffering from end stage renal disease. The program is governed by the Social Security Act of 1965 and is administered primarily by the Department of Health and Human Services (“HHS”) and CMS. Revenue generated directly from the Medicare program represented approximately 23% of our revenue for the three months ended March 31, 2023, and for the year ended December 31, 2022.

Federal Health Care Program Changes in Response to the COVID-19 Pandemic

On January 31, 2020, HHS declared a public health emergency under section 319 of the Public Health Service Act, 42 U.S.C. § 247d, in response to the COVID-19 outbreak in the United States. The HHS Secretary renewed the public health emergency determination for subsequent 90-day periods and it is now scheduled to end on May 11, 2023. The COVID-19 national emergency that was declared by President Trump on March 13, 2020, which is separate from the public health emergency, ended on April 10, 2023 when H.R.J. Res. 7 was signed into law.

As a result of the COVID-19 national emergency, the HHS Secretary authorized the waiver or modification of certain requirements under Medicare, Medicaid, and the Children’s Health Insurance Program (“CHIP”) pursuant to section 1135 of the Social Security Act. Under this authority, CMS issued a number of blanket waivers that excuse health care providers or suppliers from specific program requirements. Our Annual Report on Form 10-K for the year ended December 31, 2022 contains a detailed discussion of the federal health care program changes made in response to the COVID-19 pandemic, including these COVID-19 waivers, in Part II — Management’s Discussion and Analysis of Financial Condition and Results of Operations — Regulatory Changes. Most of these COVID-19 waivers, including the waiver of the IRF 60% Rule and the waiver of Medicare statutory requirements regarding site neutral payments to long-term care hospitals (“LTCHs”), are scheduled to end when the public health emergency expires on May 11, 2023. However, LTCHs are exempt from the greater-than-25-day average length of stay requirement for all cost reporting periods that include the COVID-19 public health emergency period. As a result, even when the public health emergency ends on May 11, 2023, LTCHs with cost reporting periods that started prior to May 11, 2023 will continue to be exempt for the remainder of that cost reporting year.

In addition, the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act and related legislation temporarily suspended the 2% cut to Medicare payments due to sequestration from May 1, 2020 through March 31, 2022 and reduced the sequestration adjustment from 2% to 1% from April 1 through June 30, 2022. The full 2% reduction resumed on July 1, 2022. To pay for this relief, Congress increased the sequestration cut to Medicare payments to 2.25% for the first six months of fiscal year 2030 and to 3% for the final six months of fiscal year 2030. Additionally, an across-the-board 4% payment cut required to take effect in January 2022 due to the American Rescue Plan from the FY 2022 Statutory Pay-As-You-Go (“PAYGO”) scorecard was deferred by Congress until 2025.

The CARES Act and related legislation also provided more than $178 billion in appropriations for the Public Health and Social Services Emergency Fund, also known as the Provider Relief Fund, to be used for preventing, preparing, and responding to COVID-19 and for reimbursing “eligible health care providers for health care related expenses or lost revenues that are attributable to coronavirus.” HHS began distributing these funds to providers in April 2020. Recipients of payments were required to report data to HHS on the use of the funds via an online portal by specific deadlines established by HHS based on the date of the payment. All recipients of funds are subject to audit by HHS, the HHS OIG, or the Pandemic Response Accountability Committee. Audits may include examination of the accuracy of the data providers submitted to HHS in their applications for payments. Additional distributions are not expected and as a result, the Company does not expect to recognize additional income associated with these funds in the future.

23

Medicare Reimbursement of LTCH Services

The following is a summary of significant regulatory changes to the Medicare prospective payment system for our critical illness recovery hospitals, which are certified by Medicare as LTCHs, which have affected our results of operations, as well as the policies and payment rates that may affect our future results of operations. Medicare payments to our critical illness recovery hospitals are made in accordance with the long-term care hospital prospective payment system (“LTCH-PPS”).

Fiscal Year 2022. On August 13, 2021, CMS published the final rule updating policies and payment rates for the LTCH-PPS for fiscal year 2022 (affecting discharges and cost reporting periods beginning on or after October 1, 2021, through September 30, 2022). The standard federal rate was set at $44,714, an increase from the standard federal rate applicable during fiscal year 2021 of $43,755. The update to the standard federal rate for fiscal year 2022 included a market basket increase of 2.6%, less a productivity adjustment of 0.7%. The standard federal rate also included an area wage budget neutrality factor of 1.002848. The fixed-loss amount for high cost outlier cases paid under LTCH-PPS was set at $33,015, an increase from the fixed-loss amount in the 2021 fiscal year of $27,195. The fixed-loss amount for high cost outlier cases paid under the site-neutral payment rate was set at $30,988, an increase from the fixed-loss amount in the 2021 fiscal year of $29,064.

Fiscal Year 2023. On August 10, 2022, CMS published the final rule updating policies and payment rates for the LTCH-PPS for fiscal year 2023 (affecting discharges and cost reporting periods beginning on or after October 1, 2022, through September 30, 2023). Certain errors in the final rule were corrected in documents published November 4, 2022, and December 13, 2022. The standard federal rate for fiscal year 2023 is $46,433, an increase from the standard federal rate applicable during fiscal year 2022 of $44,714. The update to the standard federal rate for fiscal year 2023 includes a market basket increase of 4.1%, less a productivity adjustment of 0.3%. The standard federal rate also includes an area wage budget neutrality factor of 1.0004304. As a result of the CARES Act, all LTCH cases are paid at the standard federal rate during the public health emergency. Once the public health emergency ends, which is expected to occur on May 11, 2023, CMS will return to using the site-neutral payment rate for reimbursement of cases that do not meet the LTCH patient criteria. The fixed-loss amount for high cost outlier cases paid under LTCH-PPS is $38,518, an increase from the fixed-loss amount in the 2022 fiscal year of $33,015. The fixed-loss amount for high cost outlier cases paid under the site-neutral payment rate is $38,788, an increase from the fixed-loss amount in the 2022 fiscal year of $30,988.

Fiscal Year 2024. On April 10, 2023, CMS released a display copy of the proposed rule to update policies and payment rates for the LTCH-PPS for fiscal year 2024 (affecting discharges and cost reporting periods beginning on or after October 1, 2023 through September 30, 2024). CMS is expected to issue the final rule in August or shortly thereafter. The proposed standard federal rate for fiscal year 2024 is $47,948, an increase from the standard federal rate applicable during fiscal year 2023 of $46,433. The proposed update to the standard federal rate for fiscal year 2024 includes a market basket increase of 3.1%, less a productivity adjustment of 0.2%. The proposed standard federal rate also includes an area wage budget neutrality factor of 1.0035335. The proposed fixed-loss amount for high cost outlier cases paid under LTCH-PPS is $94,378, an increase from the fixed-loss amount in the 2023 fiscal year of $38,518. The proposed fixed-loss amount for high cost outlier cases paid under the site-neutral payment rate is $40,732, an increase from the fixed-loss amount in the 2023 fiscal year of $38,788.

Medicare Reimbursement of IRF Services

The following is a summary of significant regulatory changes to the Medicare prospective payment system for our rehabilitation hospitals, which are certified by Medicare as IRFs, which have affected our results of operations, as well as the policies and payment rates that may affect our future results of operations. Medicare payments to our rehabilitation hospitals are made in accordance with the inpatient rehabilitation facility prospective payment system (“IRF-PPS”).

Fiscal Year 2022. On August 4, 2021, CMS published the final rule updating policies and payment rates for the IRF-PPS for fiscal year 2022 (affecting discharges and cost reporting periods beginning on or after October 1, 2021, through September 30, 2022). The standard payment conversion factor for discharges for fiscal year 2022 was set at $17,240, an increase from the standard payment conversion factor applicable during fiscal year 2021 of $16,856. The update to the standard payment conversion factor for fiscal year 2022 included a market basket increase of 2.6%, less a productivity adjustment of 0.7%. CMS increased the outlier threshold amount for fiscal year 2022 to $9,491 from $7,906 established in the final rule for fiscal year 2021.

Fiscal Year 2023. On August 1, 2022, CMS published the final rule updating policies and payment rates for the IRF-PPS for fiscal year 2023 (affecting discharges and cost reporting periods beginning on or after October 1, 2022, through September 30, 2023). The standard payment conversion factor for discharges for fiscal year 2023 was set at $17,878, an increase from the standard payment conversion factor applicable during fiscal year 2022 of $17,240. The update to the standard payment conversion factor for fiscal year 2023 included a market basket increase of 4.2%, less a productivity adjustment of 0.3%. CMS increased the outlier threshold amount for fiscal year 2023 to $12,526 from $9,491 established in the final rule for fiscal year 2022.

24

Fiscal Year 2024. On April 7, 2023, CMS published a proposed rule to update policies and payment rates for the IRF-PPS for fiscal year 2024 (affecting discharges and cost reporting periods beginning on or after October 1, 2023 through September 30, 2024). The standard payment conversion factor for discharges for fiscal year 2024 would be set at $18,471, an increase from the standard payment conversion factor applicable during fiscal year 2022 of $17,878. The update to the standard payment conversion factor for fiscal year 2024, if adopted, would include a market basket increase of 3.2%, less a productivity adjustment of 0.2%. CMS proposed to decrease the outlier threshold amount for fiscal year 2024 to $9,690 from $12,526 established in the final rule for fiscal year 2023.

Medicare Reimbursement of Outpatient Rehabilitation Clinic Services

Our Annual Report on Form 10-K for the year ended December 31, 2022 contains a detailed discussion of Medicare reimbursement regulations that affect our outpatient rehabilitation clinic operations in Part I — Business — Government Regulations and in Part II — Management’s Discussion and Analysis of Financial Condition and Results of Operations — Regulatory Changes. There have been no significant updates to these regulations subsequently.

Modifiers to Identify Services of Physical Therapy Assistants or Occupational Therapy Assistants

Our Annual Report on Form 10-K for the year ended December 31, 2022 contains a detailed discussion of Medicare regulations concerning services provided by physical therapy assistants and occupational therapy assistants in Part I — Business — Government Regulations and in Part II — Management’s Discussion and Analysis of Financial Condition and Results of Operations — Regulatory Changes. There have been no significant updates to these regulations subsequently.

25

Operating Statistics

The following table sets forth operating statistics for each of our segments for the periods presented. The operating statistics reflect data for the period of time we managed these operations. Our operating statistics include metrics we believe provide relevant insight about the number of facilities we operate, volume of services we provide to our patients, and average payment rates for services we provide. These metrics are utilized by management to monitor trends and performance in our businesses and therefore may be important to investors because management may assess our performance based in part on such metrics. Other healthcare providers may present similar statistics, and these statistics are susceptible to varying definitions. Our statistics as presented may not be comparable to other similarly titled statistics of other companies.

	Three Months Ended March 31,
	2022			2023
Critical illness recovery hospital data:
Number of consolidated hospitals—start of period(1)	104			103
Number of hospitals acquired	—			—
Number of hospital start-ups	1			2
Number of hospitals closed/sold	—			—
Number of consolidated hospitals—end of period(1)	105			105
Available licensed beds(3)	4,524			4,440
Admissions(3)(4)	9,457			9,438
Patient days(3)(5)	289,217			286,746
Average length of stay (days)(3)(6)	30			30
Revenue per patient day(3)(7)	$	2,075		$	2,058
Occupancy rate(3)(8)	71		%	72		%
Percent patient days—Medicare(3)(9)	37		%	39		%
Rehabilitation hospital data:
Number of consolidated hospitals—start of period(1)	20			20
Number of hospitals acquired	—			—
Number of hospital start-ups	—			—
Number of hospitals closed/sold	—			—
Number of consolidated hospitals—end of period(1)	20			20
Number of unconsolidated hospitals managed—end of period(2)	10			12
Total number of hospitals (all)—end of period	30			32
Available licensed beds(3)	1,391			1,413
Admissions(3)(4)	7,182			7,620
Patient days(3)(5)	103,802			107,910
Average length of stay (days)(3)(6)	15			14
Revenue per patient day(3)(7)	$	1,943		$	1,969
Occupancy rate(3)(8)	84		%	86		%
Percent patient days—Medicare(3)(9)	47		%	49		%
Outpatient rehabilitation data:
Number of consolidated clinics—start of period	1,572			1,622
Number of clinics acquired	2			9
Number of clinic start-ups	12			12
Number of clinics closed/sold	(2)			(11)
Number of consolidated clinics—end of period	1,584			1,632
Number of unconsolidated clinics managed—end of period	317			304
Total number of clinics (all)—end of period	1,901			1,936
Number of visits(3)(10)	2,310,086			2,636,770
Revenue per visit(3)(11)	$	102		$	101

26

	Three Months Ended March 31,
	2022		2023
Concentra data:
Number of consolidated centers—start of period	518		540
Number of centers acquired	1		—
Number of center start-ups	—		—
Number of centers closed/sold	(1)		(1)
Number of consolidated centers—end of period	518		539
Number of onsite clinics operated—end of period	140		140
Number of visits(3)(10)	3,116,898		3,217,945
Revenue per visit(3)(11)	$	125	$	133

_______________________________________________________________________________

(1)Represents the number of hospitals included in our consolidated financial results at the end of each period presented.

(2)Represents the number of hospitals which are managed by us at the end of each period presented. We have minority ownership interests in these businesses.

(3)Data excludes locations managed by the Company. For purposes of our Concentra segment, onsite clinics are excluded.

(4)Represents the number of patients admitted to our hospitals during the periods presented.

(5)Each patient day represents one patient occupying one bed for one day during the periods presented.

(6)Represents the average number of days in which patients were admitted to our hospitals. Average length of stay is calculated by dividing the number of patient days, as presented above, by the number of patients discharged from our hospitals during the periods presented.

(7)Represents the average amount of revenue recognized for each patient day. Revenue per patient day is calculated by dividing patient service revenues, excluding revenues from certain other ancillary and outpatient services provided at our hospitals, by the total number of patient days.

(8)Represents the portion of our hospitals being utilized for patient care during the periods presented. Occupancy rate is calculated using the number of patient days, as presented above, divided by the total number of bed days available during the period. Bed days available is derived by adding the daily number of available licensed beds for each of the periods presented.

(9)Represents the portion of our patient days which are paid by Medicare. The Medicare patient day percentage is calculated by dividing the total number of patient days which are paid by Medicare by the total number of patient days, as presented above.

(10)Represents the number of visits in which patients were treated at our outpatient rehabilitation clinics and Concentra centers during the periods presented. COVID-19 screening and testing services provided by our Concentra segment are not included in these figures.

(11)Represents the average amount of revenue recognized for each patient visit. Revenue per visit is calculated by dividing patient service revenue, excluding revenues from certain other ancillary services, by the total number of visits. For purposes of this computation for our Concentra segment, patient service revenue does not include onsite clinics or revenues generated from COVID-19 screening and testing services.

27

Results of Operations

The following table outlines selected operating data as a percentage of revenue for the periods indicated:

	Three Months Ended March 31,
	2022		2023
Revenue	100.0	%	100.0	%
Costs and expenses:
Cost of services, exclusive of depreciation and amortization(1)	88.0		85.2
General and administrative	2.3		2.5
Depreciation and amortization	3.2		3.2
Total costs and expenses	93.5		90.9
Income from operations	6.5		9.1
Equity in earnings of unconsolidated subsidiaries	0.3		0.5
Interest expense	(2.2)		(2.9)
Income before income taxes	4.6		6.7
Income tax expense	1.1		1.6
Net income	3.5		5.1
Net income attributable to non-controlling interests	0.4		0.8
Net income attributable to Select Medical Holdings Corporation	3.1	%	4.3	%

_______________________________________________________________________________

(1)Cost of services includes salaries, wages and benefits, operating supplies, lease and rent expense, and other operating costs.

28

The following table summarizes selected financial data by segment for the periods indicated:

		Three Months Ended March 31,
		2022			2023			% Change
	(in thousands, except percentages)
Revenue:
Critical illness recovery hospital		$	601,755		$	593,926		(1.3)	%
Rehabilitation hospital		220,634			231,462			4.9
Outpatient rehabilitation		271,940			295,903			8.8
Concentra		423,423			456,298			7.8
Other(1)		81,795			87,391			6.8
Total Company		$	1,599,547		$	1,664,980		4.1	%
Income (loss) from operations:
Critical illness recovery hospital		$	21,349		$	60,136		181.7	%
Rehabilitation hospital		35,577			40,328			13.4
Outpatient rehabilitation		18,567			21,742			17.1
Concentra		70,122			75,260			7.3
Other(1)		(41,630)			(46,009)			N/M
Total Company		$	103,985		$	151,457		45.7	%
Adjusted EBITDA:
Critical illness recovery hospital		$	35,967		$	76,773		113.5	%
Rehabilitation hospital		42,379			47,216			11.4
Outpatient rehabilitation		26,596			30,199			13.5
Concentra		89,469			93,748			4.8
Other(1)		(30,564)			(33,873)			N/M
Total Company		$	163,847		$	214,063		30.6	%
Adjusted EBITDA margins:
Critical illness recovery hospital		6.0		%	12.9		%
Rehabilitation hospital		19.2			20.4
Outpatient rehabilitation		9.8			10.2
Concentra		21.1			20.5
Other(1)		N/M			N/M
Total Company		10.2		%	12.9		%
Total assets:
Critical illness recovery hospital		$	2,367,490		$	2,507,265
Rehabilitation hospital		1,187,118			1,203,069
Outpatient rehabilitation		1,350,374			1,397,823
Concentra		2,339,940			2,300,632
Other(1)		291,022			290,947
Total Company		$	7,535,944		$	7,699,736
Purchases of property, equipment, and other assets:
Critical illness recovery hospital		$	19,569		$	23,658
Rehabilitation hospital		6,274			8,582
Outpatient rehabilitation		9,414			9,932
Concentra		10,240			14,400
Other(1)		1,348			2,313
Total Company		$	46,845		$	58,885

_______________________________________________________________________________

(1)    Other includes our corporate administration and shared services, as well as employee leasing services with our non-consolidating subsidiaries. Total assets include certain non-consolidating joint ventures and minority investments in other healthcare related businesses.

N/M — Not meaningful.

29

Three Months Ended March 31, 2023, Compared to Three Months Ended March 31, 2022

For the three months ended March 31, 2023, we had revenue of $1,665.0 million and income from operations of $151.5 million, as compared to revenue of $1,599.5 million and income from operations of $104.0 million for the three months ended March 31, 2022. For the three months ended March 31, 2023, Adjusted EBITDA was $214.1 million, with an Adjusted EBITDA margin of 12.9%, as compared to Adjusted EBITDA of $163.8 million and an Adjusted EBITDA margin of 10.2% for the three months ended March 31, 2022.

The most significant contributor to the improvement in our financial performance for the three months ended March 31, 2023, compared to the three months ended March 31, 2022, was a decrease in labor costs in our critical illness recovery hospital segment as the investments made in the recruitment, hiring, and retention of full-time staff in 2022 resulted in a significant decrease in contract labor utilization. Additionally, reduced demand in the marketplace resulted in lower contract labor rates, which further contributed to the decrease in total contract labor costs. We believe the ratio of personnel expense to net revenue for the critical illness recovery hospital segment for the three months ended March 31, 2023, is indicative of a more stabilized labor environment.

Revenue

Critical Illness Recovery Hospital Segment.   Revenue was $593.9 million for the three months ended March 31, 2023, compared to $601.8 million for the three months ended March 31, 2022. Our patient days were 286,746 for the three months ended March 31, 2023, compared to 289,217 days for the three months ended March 31, 2022. Occupancy in our critical illness recovery hospitals was 72% and 71% for the three months ended March 31, 2023 and 2022, respectively. Revenue per patient day was $2,058 for the three months ended March 31, 2023, compared to $2,075 for the three months ended March 31, 2022. Our Medicare revenue per patient day decreased during the three months ended March 31, 2023 primarily due to reinstatement of the 2.0% cut to Medicare payments due to sequestration.

Rehabilitation Hospital Segment.   Revenue increased 4.9% to $231.5 million for the three months ended March 31, 2023, compared to $220.6 million for the three months ended March 31, 2022. The increase in revenue was principally due to an increase in patient days. Our patient days increased 4.0% to 107,910 days for the three months ended March 31, 2023, compared to 103,802 days for the three months ended March 31, 2022. Occupancy in our rehabilitation hospitals was 86% and 84% for the three months ended March 31, 2023 and 2022, respectively. Our revenue per patient day increased 1.3% to $1,969 for the three months ended March 31, 2023, compared to $1,943 for the three months ended March 31, 2022. We experienced increases in both our Medicare and non-Medicare revenue per patient day during the three months ended March 31, 2023, compared to the three months ended March 31, 2022.

Outpatient Rehabilitation Segment.   Revenue increased 8.8% to $295.9 million for the three months ended March 31, 2023, compared to $271.9 million for the three months ended March 31, 2022. The increase in revenue was primarily attributable to patient visits, which increased 14.1% to 2,636,770 visits for the three months ended March 31, 2023, compared to 2,310,086 visits for the three months ended March 31, 2022. Our revenue per visit decreased to $101 for the three months ended March 31, 2023, compared to $102 for the three months ended March 31, 2022, primarily due to a decrease in Medicare reimbursement rates along with the impact of the reinstatement of the 2.0% cut to Medicare payments due to sequestration.

Concentra Segment.   Revenue increased 7.8% to $456.3 million for the three months ended March 31, 2023, compared to $423.4 million for the three months ended March 31, 2022. The increase in revenue was due to increases in both revenue per visit and patient visits. Our revenue per visit increased 6.4% to $133 for the three months ended March 31, 2023, compared to $125 for the three months ended March 31, 2022. Our patient visits increased 3.2% to 3,217,945 for the three months ended March 31, 2023, compared to 3,116,898 visits for the three months ended March 31, 2022. COVID-19 screening and testing services did not contribute to the Concentra segment’s revenue for the three months ended March 31, 2023, compared to $9.1 million of revenue from these services during the three months ended March 31, 2022.

Operating Expenses

Our operating expenses consist principally of cost of services and general and administrative expenses. Our operating expenses were $1,461.1 million, or 87.7% of revenue, for the three months ended March 31, 2023, compared to $1,444.5 million, or 90.3% of revenue, for the three months ended March 31, 2022. Our cost of services, a major component of which is labor expense, was $1,418.8 million, or 85.2% of revenue, for the three months ended March 31, 2023, compared to $1,407.0 million, or 88.0% of revenue, for the three months ended March 31, 2022. The decrease in our operating expenses relative to our revenue was principally attributable to the decreased labor costs within our critical illness recovery hospital segment, as explained further within the “Adjusted EBITDA” discussion. General and administrative expenses were $42.3 million, or 2.5% of revenue, for the three months ended March 31, 2023, compared to $37.5 million, or 2.3% of revenue, for the three months ended March 31, 2022.

30

Adjusted EBITDA

Critical Illness Recovery Hospital Segment.  Adjusted EBITDA increased 113.5% to $76.8 million for the three months ended March 31, 2023, compared to $36.0 million for the three months ended March 31, 2022. Our Adjusted EBITDA margin for the critical illness recovery hospital segment was 12.9% for the three months ended March 31, 2023, compared to 6.0% for the three months ended March 31, 2022. The increases in our Adjusted EBITDA and Adjusted EBITDA margin during the three months ended March 31, 2023, as compared to the three months ended March 31, 2022, were principally due to lower labor costs resulting from our efforts in 2022 to hire additional full-time nursing staff, improve retention among our employees, and decrease our reliance on contract labor, and lower contract labor rates due to reduced demand in the marketplace. Our total contract labor costs decreased by approximately 76.0% during the three months ended March 31, 2023, as compared to the three months ended March 31, 2022, which was driven by a 53.1% decrease in the utilization of contract registered nurses and a 42.0% decrease in the rate per hour for contract registered nurses.

Rehabilitation Hospital Segment.   Adjusted EBITDA increased 11.4% to $47.2 million for the three months ended March 31, 2023, compared to $42.4 million for the three months ended March 31, 2022. Our Adjusted EBITDA margin for the rehabilitation hospital segment was 20.4% for the three months ended March 31, 2023, compared to 19.2% for the three months ended March 31, 2022. The increase in Adjusted EBITDA for the three months ended March 31, 2023, as compared to the three months ended March 31, 2022, was primarily attributable to an increase in revenue, which was partially offset by additional labor costs associated with the increase in patient days.

Outpatient Rehabilitation Segment.   Adjusted EBITDA increased 13.5% to $30.2 million for the three months ended March 31, 2023, compared to $26.6 million for the three months ended March 31, 2022. Our Adjusted EBITDA margin for the outpatient rehabilitation segment was 10.2% for the three months ended March 31, 2023, compared to 9.8% for the three months ended March 31, 2022. The increase in our Adjusted EBITDA was primarily due to an increase in patient visits, partially offset by increases in labor costs for the three months ended March 31, 2023, as compared to the three months ended March 31, 2022.

Concentra Segment.   Adjusted EBITDA increased 4.8% to $93.7 million for the three months ended March 31, 2023, compared to $89.5 million for the three months ended March 31, 2022. Our Adjusted EBITDA margin for the Concentra segment was 20.5% for the three months ended March 31, 2023, compared to 21.1% for the three months ended March 31, 2022. The increase in Adjusted EBITDA was primarily due to an increase in revenue, partially offset by increases in labor costs for the three months ended March 31, 2023, as compared to the three months ended March 31, 2022.

Depreciation and Amortization

Depreciation and amortization expense was $52.4 million for the three months ended March 31, 2023, compared to $51.0 million for the three months ended March 31, 2022.

Income from Operations

For the three months ended March 31, 2023, we had income from operations of $151.5 million, compared to $104.0 million for the three months ended March 31, 2022. The decline in labor costs experienced within our critical illness recovery hospital segment was the primary cause of the increase in income from operations, as discussed above under “Adjusted EBITDA.”

Equity in Earnings of Unconsolidated Subsidiaries

For the three months ended March 31, 2023, we had equity in earnings of unconsolidated subsidiaries of $8.6 million, compared to $5.4 million for the three months ended March 31, 2022. The increase in equity in earnings is principally due to the improved operating performance of our rehabilitation businesses in which we are a minority owner.

Interest

Our term loan is subject to an interest rate cap, which limits the one-month LIBOR rate to 1.0% on $2.0 billion of principal outstanding under the term loan. The one-month LIBOR rate was 4.86% at March 31, 2023, compared to 0.45% at March 31, 2022. Accordingly, the interest rate cap mitigated our exposure to increases in one-month LIBOR in excess of 1.0% during the three months ended March 31, 2023. Interest expense was $48.6 million for the three months ended March 31, 2023, compared to $35.5 million for the three months ended March 31, 2022. The increase in interest expense was caused by the borrowings we made under our revolving facility, as well an increase in the one-month LIBOR rate, as described further above.

31

Income Taxes

We recorded income tax expense of $26.2 million for the three months ended March 31, 2023, which represented an effective tax rate of 23.5%. We recorded income tax expense of $17.9 million for the three months ended March 31, 2022, which represented an effective tax rate of 24.3%.

The reduction in our effective tax rate resulted principally from an increase in our income before income taxes generated from our less than wholly owned subsidiaries taxed as partnerships. For these subsidiaries, we only incur income tax expense on our share of the earnings, however the full earnings of these subsidiaries are reflected in income before income taxes on the Condensed Consolidated Statement of Operations. The downward effect of the untaxed income allocated to non-controlling interests on the effective tax rate was 3.5% for the three months ended March 31, 2023, compared to 2.5% for the three months ended March 31, 2022.

Net Income Attributable to Non-Controlling Interests

Net income attributable to non-controlling interests was $14.5 million for the three months ended March 31, 2023, compared to $6.8 million for the three months ended March 31, 2022. The increase in net income attributable to non-controlling interests was principally due an increase in the net income of our less than wholly owned subsidiaries. Many of these subsidiaries benefited from lower labor costs during the three months ended March 31, 2023, as compared to the three months ended March 31, 2022.

32

Liquidity and Capital Resources

Cash Flows for the Three Months Ended March 31, 2023 and Three Months Ended March 31, 2022

In the following, we discuss cash flows from operating activities, investing activities, and financing activities.

	Three Months Ended March 31,
	2022		2023
	(in thousands)
Cash flows provided by operating activities	$	6,337	$	51,440
Cash flows used in investing activities	(55,331)		(69,062)
Cash flows provided by financing activities	105,565		3,419
Net increase (decrease) in cash and cash equivalents	56,571		(14,203)
Cash and cash equivalents at beginning of period	74,310		97,906
Cash and cash equivalents at end of period	$	130,881	$	83,703

Operating activities provided $51.4 million of cash flows for the three months ended March 31, 2023, compared to $6.3 million of cash flows for the three months ended March 31, 2022. The cash flows from operating activities during the three months ended March 31, 2022 included the repayment of $62.9 million of Medicare advance payments. The remaining change in cash flows provided by operating activities year over year is attributable to routine changes in net working capital, partially offset by an increase in net income.

Our days sales outstanding was 54 days at March 31, 2023, compared to 55 days at December 31, 2022. Our days sales outstanding was 53 days at March 31, 2022, compared to 52 days at December 31, 2021. Our days sales outstanding will fluctuate based upon variability in our collection cycles and patient volumes.

Investing activities used $69.1 million of cash flows for the three months ended March 31, 2023. The principal uses of cash were $58.9 million for purchases of property, equipment, and other assets, and $10.2 million for investments in and acquisitions of businesses. Investing activities used $55.3 million of cash flows for the three months ended March 31, 2022. The principal uses of cash were $46.8 million for purchases of property and equipment and $8.5 million for investments in and acquisitions of businesses.

Financing activities provided $3.4 million of cash flows for the three months ended March 31, 2023. The principal source of cash was net borrowings under our revolving facility of $15.0 million and net borrowings on our other debt of $10.3 million. The principal uses of cash were $15.9 million of dividend payments to common stockholders and $8.0 million for distributions to and purchases of non-controlling interests. Financing activities provided $105.6 million of cash flows for the three months ended March 31, 2022. The principal source of cash was net borrowings under our revolving facility of $180.0 million. The principal uses of cash were $51.7 million for repurchases of common stock, $16.7 million of dividend payments to common stockholders and $10.3 million for distributions to and purchases of non-controlling interests.

33

Capital Resources

Working capital.  We had net working capital of $128.0 million at March 31, 2023, compared to $116.2 million at December 31, 2022. The increase in working capital was primarily due to an increase in accounts receivable and a decrease in our accrued expenses. This was partially offset by an increase in the current portion of our long-term debt.

Credit facilities. On February 21, 2023, Select entered into Amendment No. 6 to the Select credit agreement. Amendment No. 6 extended the maturity date on $530.0 million of the total borrowing capacity of $650.0 million under the Select revolving facility to March 6, 2025; however, in the event the Company’s term loan is not refinanced by January 3, 2025, the maturity date for those revolving borrowings will be January 3, 2025.

At March 31, 2023, Select had outstanding borrowings under its credit facilities consisting of a $2,103.4 million term loan (excluding unamortized original issue discounts and debt issuance costs of $8.1 million) and borrowings of $460.0 million under its revolving facility. At March 31, 2023, Select had $133.8 million of availability under its revolving facility after giving effect to $56.2 million of outstanding letters of credit.

Stock Repurchase Program.  Holdings’ Board of Directors has authorized a common stock repurchase program to repurchase up to $1.0 billion worth of shares of its common stock. The common stock repurchase program will remain in effect until December 31, 2023, unless further extended or earlier terminated by the Board of Directors. Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as Holdings deems appropriate. Holdings funds this program with cash on hand and borrowings under its revolving facility. Holdings did not repurchase shares during the three months ended March 31, 2023. Since the inception of the program through March 31, 2023, Holdings has repurchased 48,234,823 shares at a cost of approximately $600.3 million, or $12.45 per share, which includes transaction costs. The Inflation Reduction Act of 2022, which enacted a 1% excise tax on stock repurchases that exceed $1.0 million, became effective January 1, 2023.

Use of Capital Resources.  We may from time to time pursue opportunities to develop new joint venture relationships with large, regional health systems and other healthcare providers. We also intend to open new outpatient rehabilitation clinics and occupational health centers in local areas that we currently serve where we can benefit from existing referral relationships and brand awareness to produce incremental growth. In addition to our development activities, we may grow through opportunistic acquisitions.

Liquidity

We believe our internally generated cash flows and borrowing capacity under our revolving facility will allow us to finance our operations in both the short and long term. As of March 31, 2023, we had cash and cash equivalents of $83.7 million and $133.8 million of availability under the revolving facility after giving effect to $460.0 million of outstanding borrowings and $56.2 million of outstanding letters of credit.

We may from time to time seek to retire or purchase our outstanding debt through cash purchases and/or exchanges for equity securities, in open market purchases, privately negotiated transactions, tender offers or otherwise. Such repurchases or exchanges, if any, may be funded from operating cash flows or other sources and will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. The amounts involved may be material.

Dividend

On May 3, 2023, our Board of Directors declared a cash dividend of $0.125 per share. The dividend will be payable on or about May 31, 2023 to stockholders of record as of the close of business on May 18, 2023.

There is no assurance that future dividends will be declared. The declaration and payment of dividends in the future are at the discretion of our Board of Directors after taking into account various factors, including, but not limited to, our financial condition, operating results, available cash and current and anticipated cash needs, the terms of our indebtedness, and other factors our Board of Directors may deem to be relevant.

Effects of Inflation

The healthcare industry is labor intensive and our largest expenses are labor related costs. Wage and other expenses increase during periods of inflation and when labor shortages occur in the marketplace. We have recently experienced higher labor costs related to the current inflationary environment and competitive labor market. In addition, suppliers have passed along rising costs to us in the form of higher prices. We cannot predict our ability to pass along cost increases to our customers.

34

Recent Accounting Pronouncements

Refer to Note 2 – Accounting Policies of the notes to our condensed consolidated financial statements included herein for information regarding recent accounting pronouncements.

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are subject to interest rate risk in connection with our variable rate long-term indebtedness. Our principal interest rate exposure relates to the loans outstanding under our credit facilities, which bear interest rates that are indexed against LIBOR.

At March 31, 2023, Select had outstanding borrowings under its credit facilities consisting of a $2,103.4 million term loan (excluding unamortized original issue discounts and debt issuance costs of $8.1 million) and $460.0 million of borrowings under its revolving facility.

In order to mitigate our exposure to rising interest rates, we entered into an interest rate cap transaction to limit our one-month LIBOR rate to 1.0% on $2.0 billion of principal outstanding under our term loan. The agreement applies to interest payments through September 30, 2024. As of March 31, 2023, the one-month LIBOR rate was 4.86%. As of March 31, 2023, $103.4 million of our term loan borrowings are subject to variable interest rates.

As of March 31, 2023, each 0.25% increase in market interest rates will impact the annual interest expense on our variable rate debt by $1.4 million.

ITEM 4.  CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934) as of the end of the period covered in this report. Based on this evaluation, as of March 31, 2023, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures, including the accumulation and communication of disclosure to our principal executive officer and principal financial officer as appropriate to allow timely decisions regarding disclosure, are effective to provide reasonable assurance that material information required to be included in our periodic SEC reports is recorded, processed, summarized, and reported within the time periods specified in the relevant SEC rules and forms.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Securities Exchange Act of 1934) identified in connection with the evaluation required by Rule 13a-15(d) of the Securities Exchange Act of 1934 that occurred during the first quarter ended March 31, 2023, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system will be met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control systems, there is only reasonable assurance that our controls will succeed in achieving their goals under all potential future conditions.

35

PART II: OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Refer to the “Litigation” section contained within Note 13 – Commitments and Contingencies of the notes to our condensed consolidated financial statements included herein.

ITEM 1A. RISK FACTORS

There have been no material changes from our risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2022.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Purchases of Equity Securities by the Issuer

Holdings’ Board of Directors authorized a common stock repurchase program to repurchase up to $1.0 billion worth of shares of its common stock. The program will remain in effect until December 31, 2023, unless further extended or earlier terminated by the Board of Directors. Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as Holdings deems appropriate.

During the three months ended March 31, 2023, Holdings did not repurchase shares under the authorized common stock repurchase program. The common stock repurchase program has an available capacity of $399.7 million as of March 31, 2023.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

36

ITEM 6. EXHIBITS

Number	Description
10.1	Amendment No 6, dated as of February 21, 2023, to the Credit Agreement, dated as of March 6, 2017, by and among Select Medical Holdings Corporation, Select Medical Corporation, JPMorgan Chase Bank, N.A., as Administrative Agent and Collateral Agent, and the other lenders and issuing banks party thereto, as amended by Amendment No. 1, dated as of March 22, 2018, Amendment No. 2, dated as of October 26, 2018, Amendment No. 3, dated as of August 1, 2019, Amendment No. 4, dated as of December 10, 2019, and Amendment No. 5, dated as of June 2, 2021 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K (file No. 001-34465) filed on February 22, 2023).
10.2	Offer Letter, by and between Select Medical Corporation and Christopher S. Weigl, dated April 22, 2022 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K (file No. 001-34465), filed on March 1, 2023).
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Executive Vice President and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer, and Executive Vice President and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH	Inline XBRL Taxonomy Extension Schema Document.
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104	Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

37

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

SELECT MEDICAL HOLDINGS CORPORATION
By:	/s/ Martin F. Jackson
	Martin F. Jackson
	Executive Vice President and Chief Financial Officer
	(Duly Authorized Officer)
By:	/s/ Christopher S. Weigl
	Christopher S. Weigl
	Senior Vice President, Controller & Chief Accounting Officer
	(Principal Accounting Officer)

Dated:  May 4, 2023

38

EX-31.1

EXHIBIT 31.1

SELECT MEDICAL HOLDINGS CORPORATION

CERTIFICATIONS PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

CERTIFICATION

I, David S. Chernow, certify that:

1.    I have reviewed this quarterly report on Form 10-Q of Select Medical Holdings Corporation;

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 4, 2023	/s/ David S. Chernow
	David S. Chernow
	President and Chief Executive Officer

EX-31.2

EXHIBIT 31.2

SELECT MEDICAL HOLDINGS CORPORATION

CERTIFICATIONS PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

CERTIFICATION

I, Martin F. Jackson, certify that:

1.    I have reviewed this quarterly report on Form 10-Q of Select Medical Holdings Corporation;

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 4, 2023	/s/ Martin F. Jackson
	Martin F. Jackson
	Executive Vice President and Chief Financial Officer

EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Select Medical Holdings Corporation (the “Company”) for the period ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, David S. Chernow and Martin F. Jackson, Chief Executive Officer and Chief Financial Officer, respectively, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to our knowledge:

(1)    The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.

May 4, 2023

/s/ David S. Chernow

David S. Chernow

President and Chief Executive Officer

/s/ Martin F. Jackson

Martin F. Jackson

Executive Vice President and Chief Financial Officer

XML

Cover - shares	3 Months Ended
	Mar. 31, 2023	Apr. 30, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-34465
Entity Registrant Name	SELECT MEDICAL HOLDINGS CORP
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-1764048
Entity Address, Address Line One	4714 Gettysburg Road
Entity Address, Address Line Two	P.O. Box 2034
Entity Address, City or Town	Mechanicsburg
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	17055
City Area Code	717
Local Phone Number	972-1100
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	SEM
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		127,126,909
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001320414

XML

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 83,703	$ 97,906
Accounts receivable	997,274	941,312
Prepaid income taxes	16,893	31,868
Current portion of interest rate cap contract	72,127	74,857
Other current assets	143,736	125,370
Total Current Assets	1,313,733	1,271,313
Operating lease right-of-use assets	1,186,534	1,169,740
Property and equipment, net	987,283	1,001,440
Goodwill	3,484,594	3,484,200
Identifiable intangible assets, net	346,606	351,662
Interest rate cap contract, net of current portion	26,994	45,200
Other assets	353,992	341,738
Total Assets	7,699,736	7,665,293
Current Liabilities:
Overdrafts	31,237	31,961
Current operating lease liabilities	239,713	236,784
Current portion of long-term debt and notes payable	113,894	44,351
Accounts payable	174,101	186,729
Accrued payroll	171,815	209,789
Accrued vacation	156,433	150,695
Accrued interest	10,241	29,837
Accrued other	274,654	264,525
Income taxes payable	13,618	480
Total Current Liabilities	1,185,706	1,155,151
Non-current operating lease liabilities	1,024,676	1,008,394
Long-term debt, net of current portion	3,766,838	3,835,211
Non-current deferred tax liability	163,024	169,793
Other non-current liabilities	106,652	106,137
Total Liabilities	6,246,896	6,274,686
Commitments and contingencies (Note 13)
Redeemable non-controlling interests	34,399	34,043
Stockholders’ Equity:
Common stock, $0.001 par value, 700,000,000 shares authorized, 127,173,871 and 127,176,279 shares issued and outstanding at 2022 and 2023, respectively	127	127
Capital in excess of par	462,185	452,183
Retained earnings	635,483	581,010
Accumulated other comprehensive income	72,654	88,602
Total Stockholders’ Equity	1,170,449	1,121,922
Non-controlling interests	247,992	234,642
Total Equity	1,418,441	1,356,564
Total Liabilities and Equity	$ 7,699,736	$ 7,665,293

XML

Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	700,000,000	700,000,000
Common stock, shares issued (in shares)	127,176,279	127,173,871
Common stock, shares outstanding (in shares)	127,176,279	127,173,871

XML

Condensed Consolidated Statements of Operations (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenue	$ 1,664,980	$ 1,599,547
Costs and expenses:
Cost of services, exclusive of depreciation and amortization	1,418,819	1,407,010
General and administrative	42,279	37,513
Depreciation and amortization	52,425	51,039
Total costs and expenses	1,513,523	1,495,562
Income from operations	151,457	103,985
Other income and expense:
Equity in earnings of unconsolidated subsidiaries	8,556	5,397
Interest expense	(48,571)	(35,514)
Income before income taxes	111,442	73,868
Income tax expense	26,185	17,942
Net income	85,257	55,926
Less: Net income attributable to non-controlling interests	14,452	6,809
Net income attributable to Select Medical Holdings Corporation	$ 70,805	$ 49,117
Earnings per common share (Note 12):
Basic (in dollars per share)	$ 0.56	$ 0.37
Diluted (in dollars per share)	$ 0.56	$ 0.37

XML

Condensed Consolidated Statements of Comprehensive Income (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement of Comprehensive Income [Abstract]
Net income	$ 85,257	$ 55,926
Other comprehensive income (loss), net of tax:
Gain (loss) on interest rate cap contract	(2,696)	39,814
Reclassification adjustment for losses (gains) included in net income	(13,252)	39
Net change, net of tax benefit (expense) of $(13,284) and $5,175	(15,948)	39,853
Comprehensive income	69,309	95,779
Less: Comprehensive income attributable to non-controlling interests	14,452	6,809
Comprehensive income attributable to Select Medical Holdings Corporation	$ 54,857	$ 88,970

XML

Condensed Consolidated Statements of Comprehensive Income (unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement of Comprehensive Income [Abstract]
Tax benefit (expense) on components of other comprehensive income	$ 5,175	$ (13,284)

XML

Condensed Consolidated Statements of Changes in Equity and Income (unaudited) - USD ($) $ in Thousands	Total	Total Stockholders’ Equity	Common Stock	Capital in Excess of Par	Retained Earnings	Accumulated Other Comprehensive Income	Non-controlling Interests
Beginning balance (in shares) at Dec. 31, 2021			133,884,000
Beginning balance at Dec. 31, 2021	$ 1,325,902	$ 1,109,981	$ 134	$ 504,314	$ 593,251	$ 12,282	$ 215,921
Increase (Decrease) in Stockholders' Equity
Net income attributable to Select Medical Holdings Corporation	49,117	49,117			49,117
Net income attributable to non-controlling interests	4,891	0					4,891
Cash dividends declared for common stockholders ($0.125 per share)	(16,691)	(16,691)			(16,691)
Issuance of restricted stock (in shares)			13,000
Issuance of restricted stock	0	0	$ 0	0
Vesting of restricted stock	8,288	8,288		8,288
Repurchase of common shares (in shares)			(2,128,000)
Repurchase of common shares	(51,676)	(51,676)	$ (2)	(23,459)	(28,215)
Issuance of non-controlling interests	5,229	651		651			4,578
Non-controlling interests acquired in business combination, measurement period adjustment	12,463	0					12,463
Distributions to and purchases of non-controlling interests	(9,097)	0					(9,097)
Redemption value adjustment on non-controlling interests	(1,381)	(1,381)			(1,381)
Other comprehensive income	39,853	39,853				39,853
Other	(2)	(2)			(2)
Ending balance (in shares) at Mar. 31, 2022			131,769,000
Ending balance at Mar. 31, 2022	$ 1,366,896	1,138,140	$ 132	489,794	596,079	52,135	228,756
Beginning balance (in shares) at Dec. 31, 2022	127,173,871		127,173,000
Beginning balance at Dec. 31, 2022	$ 1,356,564	1,121,922	$ 127	452,183	581,010	88,602	234,642
Increase (Decrease) in Stockholders' Equity
Net income attributable to Select Medical Holdings Corporation	70,805	70,805			70,805
Net income attributable to non-controlling interests	12,811	0					12,811
Cash dividends declared for common stockholders ($0.125 per share)	(15,897)	(15,897)			(15,897)
Issuance of restricted stock (in shares)			3,000
Issuance of restricted stock	0	0	$ 0	0
Vesting of restricted stock	10,003	10,003		10,003
Issuance of non-controlling interests	2,731	0					2,731
Non-controlling interests acquired in business combination, measurement period adjustment	3,877	0					3,877
Distributions to and purchases of non-controlling interests	(6,069)	0					(6,069)
Redemption value adjustment on non-controlling interests	(436)	(436)			(436)
Other comprehensive income	(15,948)	(15,948)				(15,948)
Other	$ 0	0		(1)	1
Ending balance (in shares) at Mar. 31, 2023	127,176,279		127,176,000
Ending balance at Mar. 31, 2023	$ 1,418,441	$ 1,170,449	$ 127	$ 462,185	$ 635,483	$ 72,654	$ 247,992

XML

Condensed Consolidated Statements of Changes in Equity and Income (unaudited) (Parenthetical) - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement of Stockholders' Equity [Abstract]
Cash dividend declared (in dollars per share)	$ 0.125	$ 0.125

XML

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating activities
Net income	$ 85,257	$ 55,926
Adjustments to reconcile net income to net cash provided by operating activities:
Distributions from unconsolidated subsidiaries	2,566	7,486
Depreciation and amortization	52,425	51,039
Provision for expected credit losses	429	94
Equity in earnings of unconsolidated subsidiaries	(8,556)	(5,397)
Gain on sale or disposal of assets	(7)	(23)
Stock compensation expense	10,181	8,823
Amortization of debt discount, premium and issuance costs	565	558
Deferred income taxes	(2,601)	420
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	(55,397)	(52,225)
Other current assets	(11,742)	(1,819)
Other assets	3,659	2,686
Accounts payable	(4,564)	16,074
Accrued expenses	(20,775)	(14,377)
Government advances	0	(62,928)
Net cash provided by operating activities	51,440	6,337
Investing activities
Business combinations, net of cash acquired	(397)	(5,186)
Purchases of property, equipment, and other assets	(58,885)	(46,845)
Investment in businesses	(9,800)	(3,337)
Proceeds from sale of assets	20	37
Net cash used in investing activities	(69,062)	(55,331)
Financing activities
Borrowings on revolving facilities	225,000	280,000
Payments on revolving facilities	(210,000)	(100,000)
Borrowings of other debt	21,448	15,794
Principal payments on other debt	(11,170)	(9,188)
Dividends paid to common stockholders	(15,897)	(16,691)
Repurchase of common stock	0	(51,676)
Decrease in overdrafts	(724)	(7,608)
Proceeds from issuance of non-controlling interests	2,731	5,229
Distributions to and purchases of non-controlling interests	(7,969)	(10,295)
Net cash provided by financing activities	3,419	105,565
Net increase (decrease) in cash and cash equivalents	(14,203)	56,571
Cash and cash equivalents at beginning of period	97,906	74,310
Cash and cash equivalents at end of period	83,703	130,881
Supplemental information
Cash paid for interest, excluding amounts received of $17,828 under the interest rate cap contract for the three months ended March 31, 2023	84,531	53,517
Cash paid for taxes	$ 336	$ 923

XML

Condensed Consolidated Statements of Cash Flows (unaudited) (Parenthetical) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Statement of Cash Flows [Abstract]
Interest received under interest rate cash flow hedge	$ 17,828

XML

Basis of Presentation

3 Months Ended

Mar. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

Basis of Presentation

The unaudited condensed consolidated financial statements of Select Medical Holdings Corporation (“Holdings”) include the accounts of its wholly owned subsidiary, Select Medical Corporation (“Select”). Holdings conducts substantially all of its business through Select and its subsidiaries. Holdings, Select, and Select’s subsidiaries are collectively referred to as the “Company.” The unaudited condensed consolidated financial statements of the Company as of March 31, 2023, and for the three month periods ended March 31, 2022 and 2023, have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim reporting and the accounting principles generally accepted in the United States of America (“GAAP”). Accordingly, certain information and disclosures required by GAAP, which are normally included in the notes to the consolidated financial statements, have been condensed or omitted pursuant to those rules and regulations, although the Company believes the disclosure is adequate to make the information presented not misleading. In the opinion of management, such information contains all adjustments, which are normal and recurring in nature, necessary for a fair statement of the financial position, results of operations and cash flow for such periods. All significant intercompany transactions and balances have been eliminated.

The results of operations for the three months ended March 31, 2023, are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2023. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2022, contained in the Company’s Annual Report on Form 10-K filed with the SEC on February 23, 2023.

XML

Accounting Policies

3 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

Accounting Policies

Accounting Policies

Recent Accounting Guidance Not Yet Adopted

In March 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-01, Leases (Topic 842): Common Control Arrangements, which requires companies to amortize leasehold improvements associated with related party leases under common control over the useful life of the leasehold improvement to the common control group. The ASU is effective for annual reporting periods beginning on or after December 15, 2023, however, early adoption is permitted. The ASU can either be applied prospectively or retrospectively.

The Company is currently evaluating this ASU, but does not expect it to have a material impact on its consolidated financial statements upon adoption. The Company plans to adopt the ASU using the prospective method as of January 1, 2024.

Recently Adopted Accounting Guidance

Reference Rate Reform

In December 2022, FASB issued ASU 2022-06, Reference Rate Reform (Topic 848), Deferral of the Sunset Date of Topic 848, which extended the relief provided under Topic 848 to contract modifications made and hedging relationships entered into on or before December 31, 2024. The FASB had previously issued ASU 2020-04, Reference Rate Reform (Topic 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting in March 2020, which provided temporary relief from some of the existing accounting rules governing contract modifications when the modification is related to the replacement of the London Interbank Offered Rate (“LIBOR”) or other reference rates discontinued as a result of reference rate reform.

For eligible contract modifications, the update generally allows an entity to account for and present modifications as an event that does not require contract remeasurement at the modification date or reassessment of a previous accounting determination. That is, the modified contract is accounted for as a continuation of the existing contract. For cash flow hedging relationships affected by reference rate reform, Topic 848 provides expedients that allow an entity to (i) change the reference rate of either the forecasted transaction or hedging instrument without requiring dedesignation of the hedging relationship; (ii) assert that changes to the hedged forecasted transaction will not impact whether it remains probable of occurring; and (iii) for the purposes of assessment of hedge effectiveness assume that the reference rate will not be replaced for the remainder of the hedging relationship if both the hedged forecasted transaction and hedging instrument are expected to be impacted by reference rate reform.

In March 2021, the Financial Conduct Authority announced that the intended cessation date of the one-, three-, six-, and 12-month tenors of USD LIBOR is June 30, 2023. Borrowings under the Company’s credit agreement bear interest, at the election of Select, based on LIBOR or an alternate base rate. The Company currently elects for its term loan borrowings to bear interest at a rate that is indexed to one-month LIBOR. Provisions within the credit agreement provide the Company with the ability to agree with JPMorgan Chase Bank, N.A., as administrative agent to the lenders, to replace LIBOR with a different reference rate in the event that LIBOR ceases to exist. The Company has not yet agreed upon a different reference rate with JPMorgan Chase Bank, N.A.

For the Company’s cash flow hedge, which mitigates the Company’s exposure to increases in the one-month LIBOR rate above 1.0% on $2.0 billion of principal outstanding under the term loan, the Company has elected to assert that the hedged forecasted transaction remains probable of occurring, regardless of a modification or expected modification that may replace one-month LIBOR with a different reference rate. The Company intends to modify the cash flow hedge’s contractual terms related to the replacement of the reference rate, as necessary, to align with the reference rate specified for the Company’s term loan. For the purpose of the assessment of hedge effectiveness, the Company assumes that the reference rate will not be replaced for the remainder of the hedging relationship, as outlined by Topic 848. The Company’s cash flow hedge is described further in Note 8 – Interest Rate Cap.

These updates have not had, and the Company does not expect them to have in future periods, a material impact on the Company's consolidated financial statements.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. Actual results could differ from those estimates.

XML

Credit Risk Concentrations

3 Months Ended

Mar. 31, 2023

Credit Loss [Abstract]

Credit Risk Concentrations

Credit Risk Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash balances and accounts receivable. The Company’s excess cash is held with large financial institutions. The Company grants unsecured credit to its patients, most of whom reside in the service area of the Company’s facilities and are insured under third-party payor agreements.

Because of the diversity in the Company’s non-governmental third-party payor base, as well as their geographic dispersion, accounts receivable due from the Medicare program represent the Company’s only significant concentration of credit risk. Approximately 19% and 20% of the Company’s accounts receivable is due from Medicare at December 31, 2022 and March 31, 2023, respectively.

XML

Redeemable Non-Controlling Interests

3 Months Ended

Mar. 31, 2023

Noncontrolling Interest [Abstract]

Redeemable Non-Controlling Interests

Redeemable Non-Controlling Interests

The ownership interests held by outside parties in subsidiaries, which include limited liability companies and limited partnerships, controlled by the Company are classified as non-controlling interests. Some of the Company’s non-controlling ownership interests consist of outside parties that have certain redemption rights that, if exercised, require the Company to purchase the parties’ ownership interests. These interests are classified and reported as redeemable non-controlling interests and have been adjusted to their approximate redemption values, after the attribution of net income or loss.

The changes in redeemable non-controlling interests are as follows:

	Three Months Ended March 31,
	2022		2023
	(in thousands)
Balance as of January 1	$	39,033	$	34,043
Net income attributable to redeemable non-controlling interests	1,918		1,641
Distributions to redeemable non-controlling interests	(1,198)		(1,900)
Redemption value adjustment on redeemable non-controlling interests	1,381		436
Other	536		179
Balance as of March 31	$	41,670	$	34,399

XML

Variable Interest Entities

3 Months Ended

Mar. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Variable Interest Entities

Variable Interest Entities

Certain states prohibit the “corporate practice of medicine,” which restricts the Company from owning medical practices which directly employ physicians or therapists and from exercising control over medical decisions by physicians and therapists. In these states, the Company enters into long-term management agreements with medical practices that are owned by licensed physicians or therapists, which, in turn, employ or contract with physicians or therapists who provide professional medical services. The management agreements provide for the Company to direct the transfer of ownership of the medical practices. Based on the provisions of the management agreements, the medical practices are variable interest entities for which the Company is the primary beneficiary.

As of December 31, 2022, and March 31, 2023, the total assets of the Company’s variable interest entities were $232.1 million and $254.1 million, respectively, and are principally comprised of accounts receivable. As of December 31, 2022, and March 31, 2023, the total liabilities of the Company’s variable interest entities were $78.8 million and $82.2 million, respectively, and are principally comprised of accounts payable and accrued expenses. These variable interest entities have obligations payable for services received under their management agreements with the Company of $158.3 million and $178.4 million as of December 31, 2022, and March 31, 2023, respectively. These intercompany balances are eliminated in consolidation.

XML

Leases

3 Months Ended

Mar. 31, 2023

Leases [Abstract]

Leases

Leases

The Company has operating and finance leases for its facilities. The Company leases its corporate office space from related parties.

The Company’s total lease cost is as follows:

	Three Months Ended March 31, 2022						Three Months Ended March 31, 2023
	Unrelated Parties		Related Parties		Total		Unrelated Parties		Related Parties		Total
	(in thousands)
Operating lease cost	$	73,962	$	1,809	$	75,771	$	76,632	$	1,834	$	78,466
Finance lease cost:
Amortization of right-of-use assets	347		—		347		394		—		394
Interest on lease liabilities	340		—		340		320		—		320
Short-term lease cost	35		—		35		—		—		—
Variable lease cost	13,655		39		13,694		15,761		84		15,845
Sublease income	(1,966)		—		(1,966)		(1,678)		—		(1,678)
Total lease cost	$	86,373	$	1,848	$	88,221	$	91,429	$	1,918	$	93,347

Leases

Leases

The Company has operating and finance leases for its facilities. The Company leases its corporate office space from related parties.

The Company’s total lease cost is as follows:

	Three Months Ended March 31, 2022						Three Months Ended March 31, 2023
	Unrelated Parties		Related Parties		Total		Unrelated Parties		Related Parties		Total
	(in thousands)
Operating lease cost	$	73,962	$	1,809	$	75,771	$	76,632	$	1,834	$	78,466
Finance lease cost:
Amortization of right-of-use assets	347		—		347		394		—		394
Interest on lease liabilities	340		—		340		320		—		320
Short-term lease cost	35		—		35		—		—		—
Variable lease cost	13,655		39		13,694		15,761		84		15,845
Sublease income	(1,966)		—		(1,966)		(1,678)		—		(1,678)
Total lease cost	$	86,373	$	1,848	$	88,221	$	91,429	$	1,918	$	93,347

XML

Long-Term Debt and Notes Payable

3 Months Ended

Mar. 31, 2023

Debt Disclosure [Abstract]

Long-Term Debt and Notes Payable

Long-Term Debt and Notes Payable

As of March 31, 2023, the Company’s long-term debt and notes payable are as follows:

	Principal Outstanding		Unamortized Premium (Discount)		Unamortized Issuance Costs		Carrying Value		Fair Value
	(in thousands)
6.250% senior notes	$	1,225,000	$	20,065	$	(10,206)	$	1,234,859	$	1,188,250
Credit facilities:
Revolving facility	460,000		—		—		460,000		458,275
Term loan	2,103,437		(3,881)		(4,230)		2,095,326		2,095,549
Other debt, including finance leases	90,664		—		(117)		90,547		90,547
Total debt	$	3,879,101	$	16,184	$	(14,553)	$	3,880,732	$	3,832,621

Principal maturities of the Company’s long-term debt and notes payable are approximately as follows:

	2023		2024		2025		2026		2027		Thereafter		Total
	(in thousands)
6.250% senior notes	$	—	$	—	$	—	$	1,225,000	$	—	$	—	$	1,225,000
Credit facilities:
Revolving facility	—		84,923		375,077		—		—		—		460,000
Term loan	4,757		11,150		2,087,530		—		—		—		2,103,437
Other debt, including finance leases	19,928		56,356		1,408		1,308		823		10,841		90,664
Total debt	$	24,685	$	152,429	$	2,464,015	$	1,226,308	$	823	$	10,841	$	3,879,101

As of December 31, 2022, the Company’s long-term debt and notes payable are as follows:

	Principal Outstanding		Unamortized Premium (Discount)		Unamortized Issuance Costs		Carrying Value		Fair Value
	(in thousands)
6.250% senior notes	$	1,225,000	$	21,555	$	(10,948)	$	1,235,607	$	1,163,689
Credit facilities:
Revolving facility	445,000		—		—		445,000		443,331
Term loan	2,103,437		(4,376)		(4,771)		2,094,290		2,056,110
Other debt, including finance leases	104,800		—		(135)		104,665		104,665
Total debt	$	3,878,237	$	17,179	$	(15,854)	$	3,879,562	$	3,767,795

Select Credit Facilities

On February 21, 2023, Select entered into Amendment No. 6 to its senior secured credit agreement (the “Select credit agreement”). Amendment No. 6 extended the maturity date on $530.0 million of the total borrowing capacity of $650.0 million under its revolving credit facility (the “Select revolving facility”) to March 6, 2025; however, in the event the Company’s term loan is not refinanced by January 3, 2025, the maturity date for those revolving borrowings will be January 3, 2025.

XML

Interest Rate Cap

3 Months Ended

Mar. 31, 2023

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Interest Rate Cap

Interest Rate Cap

The Company is subject to market risk exposure arising from changes in interest rates on its term loan, which bears interest at a rate that is indexed to one-month LIBOR. The Company’s objective in using an interest rate derivative is to mitigate its exposure to increases in interest rates. The interest rate cap limits the Company’s exposure to increases in the one-month LIBOR rate to 1.0% on $2.0 billion of principal outstanding under the term loan, as the interest rate cap provides for payments from the counterparty when interest rates rise above 1.0%. The interest rate cap has a $2.0 billion notional amount and is effective through September 30, 2024. The Company will pay a monthly premium for the interest rate cap over the term of the agreement. The annual premium is equal to 0.0916% of the notional amount, or approximately $1.8 million.

The interest rate cap has been designated as a cash flow hedge and is highly effective at offsetting the changes in cash outflows when one-month LIBOR exceeds 1.0%. Changes in the fair value of the interest rate cap, net of tax, are recognized in other comprehensive income and are reclassified out of accumulated other comprehensive income and into interest expense when the hedged interest obligations affect earnings.

The following table outlines the changes in accumulated other comprehensive income (loss), net of tax, during the periods presented:

	Three Months Ended March 31,
	2022		2023
	(in thousands)
Balance as of January 1	$	12,282	$	88,602
Gain (loss) on interest rate cap cash flow hedge	39,814		(2,696)
Amounts reclassified from accumulated other comprehensive income	39		(13,252)
Balance as of March 31	$	52,135	$	72,654

The effects on net income of amounts reclassified from accumulated other comprehensive income are as follows:

	Three Months Ended March 31,
Statement of Operations	2022		2023
	(in thousands)
Gains (losses) included in interest expense	$	(51)	$	17,552
Income tax benefit (expense)	12		(4,300)
Amounts reclassified from accumulated other comprehensive income	$	(39)	$	13,252

The Company expects that approximately $71.1 million of estimated pre-tax gains will be reclassified from accumulated other comprehensive income into interest expense within the next twelve months.

Refer to Note 9 – Fair Value of Financial Instruments for information on the fair value of the Company’s interest rate cap contract and its balance sheet classification.

XML

Fair Value of Financial Instruments

3 Months Ended

Mar. 31, 2023

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Financial instruments which are measured at fair value, or for which a fair value is disclosed, are classified in the fair value hierarchy, as outlined below, on the basis of the observability of the inputs used in the fair value measurement:

•Level 1 – inputs are based upon quoted prices for identical instruments in active markets.

•Level 2 – inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data.

•Level 3 – inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the instrument.

The Company’s interest rate cap contract is recorded at its fair value in the condensed consolidated balance sheets on a recurring basis. The fair value of the interest rate cap contract is based upon a model-derived valuation using observable market inputs, such as interest rates and interest rate volatility, and the strike price.

Financial Instrument	Balance Sheet Classification	Level	December 31, 2022		March 31, 2023
Asset:			(in thousands)
Interest rate cap contract, current portion	Current portion of interest rate cap contract	Level 2	$	74,857	$	72,127
Interest rate cap contract, non-current portion	Interest rate cap contract, net of current portion	Level 2	45,200		26,994

The Company does not measure its indebtedness at fair value in its condensed consolidated balance sheets. The fair value of the credit facilities is based on quoted market prices for this debt in the syndicated loan market. The fair value of the senior notes is based on quoted market prices. The carrying value of the Company’s other debt, as disclosed in Note 7 – Long-Term Debt and Notes Payable, approximates fair value.

		December 31, 2022				March 31, 2023
Financial Instrument	Level	Carrying Value		Fair Value		Carrying Value		Fair Value
		(in thousands)
6.250% senior notes	Level 2	$	1,235,607	$	1,163,689	$	1,234,859	$	1,188,250
Credit facilities:
Revolving facility	Level 2	445,000		443,331		460,000		458,275
Term loan	Level 2	2,094,290		2,056,110		2,095,326		2,095,549

The Company’s other financial instruments, which primarily consist of cash and cash equivalents, accounts receivable, and accounts payable, approximate fair value because of the short-term maturities of these instruments.

XML

Segment Information

3 Months Ended

Mar. 31, 2023

Segment Reporting [Abstract]

Segment Information

Segment Information

The Company’s reportable segments consist of the critical illness recovery hospital segment, rehabilitation hospital segment, outpatient rehabilitation segment, and Concentra segment. Other activities include the Company’s corporate shared services, certain investments, and employee leasing services with non-consolidating subsidiaries.

The Company evaluates the performance of its segments based on Adjusted EBITDA. Adjusted EBITDA is defined as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries. The Company has provided additional information regarding its reportable segments, such as total assets, which contributes to the understanding of the Company and provides useful information to the users of the consolidated financial statements.

The following tables summarize selected financial data for the Company’s reportable segments.

	Three Months Ended March 31,
	2022		2023
	(in thousands)
Revenue:
Critical illness recovery hospital	$	601,755	$	593,926
Rehabilitation hospital	220,634		231,462
Outpatient rehabilitation	271,940		295,903
Concentra	423,423		456,298
Other	81,795		87,391
Total Company	$	1,599,547	$	1,664,980
Adjusted EBITDA:
Critical illness recovery hospital	$	35,967	$	76,773
Rehabilitation hospital	42,379		47,216
Outpatient rehabilitation	26,596		30,199
Concentra	89,469		93,748
Other	(30,564)		(33,873)
Total Company	$	163,847	$	214,063
Total assets:
Critical illness recovery hospital	$	2,367,490	$	2,507,265
Rehabilitation hospital	1,187,118		1,203,069
Outpatient rehabilitation	1,350,374		1,397,823
Concentra	2,339,940		2,300,632
Other	291,022		290,947
Total Company	$	7,535,944	$	7,699,736
Purchases of property, equipment, and other assets:
Critical illness recovery hospital	$	19,569	$	23,658
Rehabilitation hospital	6,274		8,582
Outpatient rehabilitation	9,414		9,932
Concentra	10,240		14,400
Other	1,348		2,313
Total Company	$	46,845	$	58,885

A reconciliation of Adjusted EBITDA to income before income taxes is as follows:

	Three Months Ended March 31, 2022
	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra		Other		Total
	(in thousands)
Adjusted EBITDA	$	35,967	$	42,379	$	26,596	$	89,469	$	(30,564)
Depreciation and amortization	(14,618)		(6,802)		(8,029)		(18,812)		(2,778)
Stock compensation expense	—		—		—		(535)		(8,288)
Income (loss) from operations	$	21,349	$	35,577	$	18,567	$	70,122	$	(41,630)	$	103,985
Equity in earnings of unconsolidated subsidiaries											5,397
Interest expense											(35,514)
Income before income taxes											$	73,868

	Three Months Ended March 31, 2023
	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra		Other		Total
	(in thousands)
Adjusted EBITDA	$	76,773	$	47,216	$	30,199	$	93,748	$	(33,873)
Depreciation and amortization	(16,637)		(6,888)		(8,457)		(18,310)		(2,133)
Stock compensation expense	—		—		—		(178)		(10,003)
Income (loss) from operations	$	60,136	$	40,328	$	21,742	$	75,260	$	(46,009)	$	151,457
Equity in earnings of unconsolidated subsidiaries											8,556
Interest expense											(48,571)
Income before income taxes											$	111,442

XML

Revenue from Contracts with Customers

3 Months Ended

Mar. 31, 2023

Revenue from Contract with Customer [Abstract]

Revenue from Contracts with Customers

Revenue from Contracts with Customers

The following tables disaggregate the Company’s revenue for the three months ended March 31, 2022 and 2023:

	Three Months Ended March 31, 2022
	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra		Other		Total
	(in thousands)
Patient service revenue:
Medicare	$	218,987	$	103,021	$	41,904	$	177	$	—	$	364,089
Non-Medicare	380,986		107,142		214,113		422,046		—		1,124,287
Total patient services revenues	599,973		210,163		256,017		422,223		—		1,488,376
Other revenue	1,782		10,471		15,923		1,200		81,795		111,171
Total revenue	$	601,755	$	220,634	$	271,940	$	423,423	$	81,795	$	1,599,547

	Three Months Ended March 31, 2023
	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra		Other		Total
	(in thousands)
Patient service revenue:
Medicare	$	229,383	$	110,055	$	45,801	$	243	$	—	$	385,482
Non-Medicare	363,305		109,925		231,985		454,598		—		1,159,813
Total patient services revenues	592,688		219,980		277,786		454,841		—		1,545,295
Other revenue	1,238		11,482		18,117		1,457		87,391		119,685
Total revenue	$	593,926	$	231,462	$	295,903	$	456,298	$	87,391	$	1,664,980

XML

Earnings per Share

3 Months Ended

Mar. 31, 2023

Earnings Per Share [Abstract]

Earnings per Share

Earnings per Share

The Company’s capital structure includes common stock and unvested restricted stock awards. To compute earnings per share (“EPS”), the Company applies the two-class method because the Company’s unvested restricted stock awards are participating securities which are entitled to participate equally with the Company’s common stock in undistributed earnings. Application of the Company’s two-class method is as follows:

(i)Net income attributable to the Company is reduced by the amount of dividends declared and by the contractual amount of dividends that must be paid for the current period for each class of stock. There were no contractual dividends paid for the three months ended March 31, 2022 and 2023.

(ii)The remaining undistributed net income of the Company is then equally allocated to its common stock and unvested restricted stock awards, as if all of the earnings for the period had been distributed. The total net income allocated to each security is determined by adding both distributed and undistributed net income for the period.

(iii)The net income allocated to each security is then divided by the weighted average number of outstanding shares for the period to determine the EPS for each security considered in the two-class method.

The following table sets forth the net income attributable to the Company, its common shares outstanding, and its participating securities outstanding.

		Basic and Diluted EPS
		Three Months Ended March 31,
		2022		2023
	(in thousands)
Net income		$	55,926	$	85,257
Less: net income attributable to non-controlling interests		6,809		14,452
Net income attributable to the Company		49,117		70,805
Less: Distributed and undistributed income attributable to participating securities		1,643		2,573
Distributed and undistributed income attributable to common shares		$	47,474	$	68,232

The following tables set forth the computation of EPS under the two-class method:

	Three Months Ended March 31,
	2022					2023
	Net Income Allocation		Shares(1)	Basic and Diluted EPS		Net Income Allocation		Shares(1)	Basic and Diluted EPS
	(in thousands, except for per share amounts)
Common shares	$	47,474	129,010	$	0.37	$	68,232	122,553	$	0.56
Participating securities	1,643		4,464	$	0.37	2,573		4,622	$	0.56
Total Company	$	49,117				$	70,805

_______________________________________________________________________________

(1)    Represents the weighted average share count outstanding during the period.

XML

Commitments and Contingencies

3 Months Ended

Mar. 31, 2023

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Commitments and Contingencies

Litigation

The Company is a party to various legal actions, proceedings, and claims (some of which are not insured), and regulatory and other governmental audits and investigations in the ordinary course of its business. The Company cannot predict the ultimate outcome of pending litigation, proceedings, and regulatory and other governmental audits and investigations. These matters could potentially subject the Company to sanctions, damages, recoupments, fines, and other penalties. The Department of Justice, Centers for Medicare & Medicaid Services (“CMS”), or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company’s businesses in the future that may, either individually or in the aggregate, have a material adverse effect on the Company’s business, financial position, results of operations, and liquidity.

To address claims arising out of the Company’s operations, the Company maintains professional malpractice liability insurance and general liability insurance coverages through a number of different programs that are dependent upon such factors as the state where the Company is operating and whether the operations are wholly owned or are operated through a joint venture. For the Company’s wholly owned hospital and outpatient clinic operations, the Company currently maintains insurance coverages under a combination of policies with a total annual aggregate limit of up to $37.0 million for professional malpractice liability insurance and $40.0 million for general liability insurance. For the Company’s Concentra center operations, the Company currently maintains insurance coverages under a combination of policies with a total annual aggregate limit of up to $19.0 million for professional malpractice liability insurance and $19.0 million for general liability insurance. The Company’s insurance for the professional liability coverage is written on a “claims-made” basis, and its commercial general liability coverage is maintained on an “occurrence” basis. These coverages apply after a self-insured retention limit is exceeded. For the Company’s joint venture operations, the Company has designed a separate insurance program that responds to the risks of specific joint ventures. Most of the Company’s joint ventures are insured under a master program with an annual aggregate limit of up to $80.0 million, subject to a sublimit aggregate ranging from $23.0 million to $33.0 million for most joint ventures. The policies are generally written on a “claims-made” basis. Each of these programs has either a deductible or self-insured retention limit. The Company also maintains additional types of liability insurance covering claims which, due to their nature or amount, are not covered by or not fully covered by the Company’s professional and general liability insurance policies. These insurance policies also do not generally cover punitive damages and are subject to various deductibles and policy limits. The Company reviews its insurance program annually and may make adjustments to the amount of insurance coverage and self-insured retentions in future years. Significant legal actions, as well as the cost and possible lack of available insurance, could subject the Company to substantial uninsured liabilities. In the Company’s opinion, the outcome of these actions, individually or in the aggregate, will not have a material adverse effect on its financial position, results of operations, or cash flows.

Healthcare providers are subject to lawsuits under the qui tam provisions of the federal False Claims Act. Qui tam lawsuits typically remain under seal (hence, usually unknown to the defendant) for some time while the government decides whether or not to intervene on behalf of a private qui tam plaintiff (known as a relator) and take the lead in the litigation. These lawsuits can involve significant monetary damages and penalties and award bounties to private plaintiffs who successfully bring the suits. The Company is and has been a defendant in these cases in the past, and may be named as a defendant in similar cases from time to time in the future.

Oklahoma City Subpoena. On August 24, 2020, the Company and Select Specialty Hospital – Oklahoma City, Inc. (“SSH–Oklahoma City”) received Civil Investigative Demands (“CIDs”) from the U.S. Attorney’s Office for the Western District of Oklahoma seeking responses to interrogatories and the production of various documents principally relating to the documentation, billing and reviews of medical services furnished to patients at SSH-Oklahoma City. The Company understands that the investigation arose from a qui tam lawsuit alleging billing fraud related to charges for respiratory therapy services at SSH-Oklahoma City and Select Specialty Hospital - Wichita, Inc. The Company has produced documents in response to the CIDs and is fully cooperating with this investigation. At this time, the Company is unable to predict the timing and outcome of this matter.

Physical Therapy Billing. On October 7, 2021, the Company received a letter from a Trial Attorney at the U.S. Department of Justice, Civil Division, Commercial Litigation Branch, Fraud Section (“DOJ”) stating that the DOJ, in conjunction with the U.S. Department of Health and Human Services (“HHS”), is investigating the Company in connection with potential violations of the False Claims Act, 31 U.S.C. § 3729, et seq. The letter specified that the investigation relates to the Company’s billing for physical therapy services, and indicated that the DOJ would be requesting certain records from the Company. In 2021, the DOJ requested, and the Company furnished, records relating to six of the Company’s outpatient therapy clinics in Florida. In 2022, the DOJ requested certain data relating to all of the Company’s outpatient therapy clinics nationwide, and sought information about the Company’s ability to produce additional data relating to the physical therapy services furnished by the Company’s outpatient therapy clinics and Concentra. The Company continues to produce data and other documents requested by the DOJ and is fully cooperating on this investigation. At this time, the Company is unable to predict the timing and outcome of this matter.

XML

Subsequent Event	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event On May 3, 2023, the Company’s Board of Directors declared a cash dividend of $0.125 per share. The dividend will be payable on or about May 31, 2023, to stockholders of record as of the close of business on May 18, 2023.

XML

Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

Recent Accounting Guidance Not Yet Adopted and Recently Adopted Accounting Guidance

Recent Accounting Guidance Not Yet Adopted

In March 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-01, Leases (Topic 842): Common Control Arrangements, which requires companies to amortize leasehold improvements associated with related party leases under common control over the useful life of the leasehold improvement to the common control group. The ASU is effective for annual reporting periods beginning on or after December 15, 2023, however, early adoption is permitted. The ASU can either be applied prospectively or retrospectively.

The Company is currently evaluating this ASU, but does not expect it to have a material impact on its consolidated financial statements upon adoption. The Company plans to adopt the ASU using the prospective method as of January 1, 2024.

Recently Adopted Accounting Guidance

Reference Rate Reform

In December 2022, FASB issued ASU 2022-06, Reference Rate Reform (Topic 848), Deferral of the Sunset Date of Topic 848, which extended the relief provided under Topic 848 to contract modifications made and hedging relationships entered into on or before December 31, 2024. The FASB had previously issued ASU 2020-04, Reference Rate Reform (Topic 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting in March 2020, which provided temporary relief from some of the existing accounting rules governing contract modifications when the modification is related to the replacement of the London Interbank Offered Rate (“LIBOR”) or other reference rates discontinued as a result of reference rate reform.

For eligible contract modifications, the update generally allows an entity to account for and present modifications as an event that does not require contract remeasurement at the modification date or reassessment of a previous accounting determination. That is, the modified contract is accounted for as a continuation of the existing contract. For cash flow hedging relationships affected by reference rate reform, Topic 848 provides expedients that allow an entity to (i) change the reference rate of either the forecasted transaction or hedging instrument without requiring dedesignation of the hedging relationship; (ii) assert that changes to the hedged forecasted transaction will not impact whether it remains probable of occurring; and (iii) for the purposes of assessment of hedge effectiveness assume that the reference rate will not be replaced for the remainder of the hedging relationship if both the hedged forecasted transaction and hedging instrument are expected to be impacted by reference rate reform.

In March 2021, the Financial Conduct Authority announced that the intended cessation date of the one-, three-, six-, and 12-month tenors of USD LIBOR is June 30, 2023. Borrowings under the Company’s credit agreement bear interest, at the election of Select, based on LIBOR or an alternate base rate. The Company currently elects for its term loan borrowings to bear interest at a rate that is indexed to one-month LIBOR. Provisions within the credit agreement provide the Company with the ability to agree with JPMorgan Chase Bank, N.A., as administrative agent to the lenders, to replace LIBOR with a different reference rate in the event that LIBOR ceases to exist. The Company has not yet agreed upon a different reference rate with JPMorgan Chase Bank, N.A.

For the Company’s cash flow hedge, which mitigates the Company’s exposure to increases in the one-month LIBOR rate above 1.0% on $2.0 billion of principal outstanding under the term loan, the Company has elected to assert that the hedged forecasted transaction remains probable of occurring, regardless of a modification or expected modification that may replace one-month LIBOR with a different reference rate. The Company intends to modify the cash flow hedge’s contractual terms related to the replacement of the reference rate, as necessary, to align with the reference rate specified for the Company’s term loan. For the purpose of the assessment of hedge effectiveness, the Company assumes that the reference rate will not be replaced for the remainder of the hedging relationship, as outlined by Topic 848. The Company’s cash flow hedge is described further in Note 8 – Interest Rate Cap.

These updates have not had, and the Company does not expect them to have in future periods, a material impact on the Company's consolidated financial statements.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. Actual results could differ from those estimates.

Credit Risk Concentrations

Credit Risk ConcentrationsFinancial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash balances and accounts receivable. The Company’s excess cash is held with large financial institutions. The Company grants unsecured credit to its patients, most of whom reside in the service area of the Company’s facilities and are insured under third-party payor agreements.Because of the diversity in the Company’s non-governmental third-party payor base, as well as their geographic dispersion, accounts receivable due from the Medicare program represent the Company’s only significant concentration of credit risk.

Redeemable Non-Controlling Interests

Redeemable Non-Controlling InterestsThe ownership interests held by outside parties in subsidiaries, which include limited liability companies and limited partnerships, controlled by the Company are classified as non-controlling interests. Some of the Company’s non-controlling ownership interests consist of outside parties that have certain redemption rights that, if exercised, require the Company to purchase the parties’ ownership interests. These interests are classified and reported as redeemable non-controlling interests and have been adjusted to their approximate redemption values, after the attribution of net income or loss.

Variable Interest Entities

Variable Interest EntitiesCertain states prohibit the “corporate practice of medicine,” which restricts the Company from owning medical practices which directly employ physicians or therapists and from exercising control over medical decisions by physicians and therapists. In these states, the Company enters into long-term management agreements with medical practices that are owned by licensed physicians or therapists, which, in turn, employ or contract with physicians or therapists who provide professional medical services. The management agreements provide for the Company to direct the transfer of ownership of the medical practices. Based on the provisions of the management agreements, the medical practices are variable interest entities for which the Company is the primary beneficiary.

XML

Redeemable Non-Controlling Interests (Tables)

3 Months Ended

Mar. 31, 2023

Noncontrolling Interest [Abstract]

Schedule of redeemable non-controlling interests

The changes in redeemable non-controlling interests are as follows:

	Three Months Ended March 31,
	2022		2023
	(in thousands)
Balance as of January 1	$	39,033	$	34,043
Net income attributable to redeemable non-controlling interests	1,918		1,641
Distributions to redeemable non-controlling interests	(1,198)		(1,900)
Redemption value adjustment on redeemable non-controlling interests	1,381		436
Other	536		179
Balance as of March 31	$	41,670	$	34,399

XML

Leases (Tables)

3 Months Ended

Mar. 31, 2023

Leases [Abstract]

Schedule of lease cost

The Company’s total lease cost is as follows:

	Three Months Ended March 31, 2022						Three Months Ended March 31, 2023
	Unrelated Parties		Related Parties		Total		Unrelated Parties		Related Parties		Total
	(in thousands)
Operating lease cost	$	73,962	$	1,809	$	75,771	$	76,632	$	1,834	$	78,466
Finance lease cost:
Amortization of right-of-use assets	347		—		347		394		—		394
Interest on lease liabilities	340		—		340		320		—		320
Short-term lease cost	35		—		35		—		—		—
Variable lease cost	13,655		39		13,694		15,761		84		15,845
Sublease income	(1,966)		—		(1,966)		(1,678)		—		(1,678)
Total lease cost	$	86,373	$	1,848	$	88,221	$	91,429	$	1,918	$	93,347

XML

Long-Term Debt and Notes Payable (Tables)

3 Months Ended

Mar. 31, 2023

Debt Disclosure [Abstract]

Schedule of long-term debt and notes payable

As of March 31, 2023, the Company’s long-term debt and notes payable are as follows:

	Principal Outstanding		Unamortized Premium (Discount)		Unamortized Issuance Costs		Carrying Value		Fair Value
	(in thousands)
6.250% senior notes	$	1,225,000	$	20,065	$	(10,206)	$	1,234,859	$	1,188,250
Credit facilities:
Revolving facility	460,000		—		—		460,000		458,275
Term loan	2,103,437		(3,881)		(4,230)		2,095,326		2,095,549
Other debt, including finance leases	90,664		—		(117)		90,547		90,547
Total debt	$	3,879,101	$	16,184	$	(14,553)	$	3,880,732	$	3,832,621

As of December 31, 2022, the Company’s long-term debt and notes payable are as follows:

	Principal Outstanding		Unamortized Premium (Discount)		Unamortized Issuance Costs		Carrying Value		Fair Value
	(in thousands)
6.250% senior notes	$	1,225,000	$	21,555	$	(10,948)	$	1,235,607	$	1,163,689
Credit facilities:
Revolving facility	445,000		—		—		445,000		443,331
Term loan	2,103,437		(4,376)		(4,771)		2,094,290		2,056,110
Other debt, including finance leases	104,800		—		(135)		104,665		104,665
Total debt	$	3,878,237	$	17,179	$	(15,854)	$	3,879,562	$	3,767,795

Schedule of principal maturities of long-term debt and notes payable

Principal maturities of the Company’s long-term debt and notes payable are approximately as follows:

	2023		2024		2025		2026		2027		Thereafter		Total
	(in thousands)
6.250% senior notes	$	—	$	—	$	—	$	1,225,000	$	—	$	—	$	1,225,000
Credit facilities:
Revolving facility	—		84,923		375,077		—		—		—		460,000
Term loan	4,757		11,150		2,087,530		—		—		—		2,103,437
Other debt, including finance leases	19,928		56,356		1,408		1,308		823		10,841		90,664
Total debt	$	24,685	$	152,429	$	2,464,015	$	1,226,308	$	823	$	10,841	$	3,879,101

XML

Interest Rate Cap (Tables)

3 Months Ended

Mar. 31, 2023

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of accumulated other comprehensive income (loss)

The following table outlines the changes in accumulated other comprehensive income (loss), net of tax, during the periods presented:

	Three Months Ended March 31,
	2022		2023
	(in thousands)
Balance as of January 1	$	12,282	$	88,602
Gain (loss) on interest rate cap cash flow hedge	39,814		(2,696)
Amounts reclassified from accumulated other comprehensive income	39		(13,252)
Balance as of March 31	$	52,135	$	72,654

Schedule of reclassification out of accumulated other comprehensive income

The effects on net income of amounts reclassified from accumulated other comprehensive income are as follows:

	Three Months Ended March 31,
Statement of Operations	2022		2023
	(in thousands)
Gains (losses) included in interest expense	$	(51)	$	17,552
Income tax benefit (expense)	12		(4,300)
Amounts reclassified from accumulated other comprehensive income	$	(39)	$	13,252

XML

Fair Value of Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2023

Fair Value Disclosures [Abstract]

Schedule of interest rate cap

Financial Instrument	Balance Sheet Classification	Level	December 31, 2022		March 31, 2023
Asset:			(in thousands)
Interest rate cap contract, current portion	Current portion of interest rate cap contract	Level 2	$	74,857	$	72,127
Interest rate cap contract, non-current portion	Interest rate cap contract, net of current portion	Level 2	45,200		26,994

Schedule of long-term debt

		December 31, 2022				March 31, 2023
Financial Instrument	Level	Carrying Value		Fair Value		Carrying Value		Fair Value
		(in thousands)
6.250% senior notes	Level 2	$	1,235,607	$	1,163,689	$	1,234,859	$	1,188,250
Credit facilities:
Revolving facility	Level 2	445,000		443,331		460,000		458,275
Term loan	Level 2	2,094,290		2,056,110		2,095,326		2,095,549

XML

Segment Information (Tables)

3 Months Ended

Mar. 31, 2023

Segment Reporting [Abstract]

Schedule of selected financial data for reportable segments

The following tables summarize selected financial data for the Company’s reportable segments.

	Three Months Ended March 31,
	2022		2023
	(in thousands)
Revenue:
Critical illness recovery hospital	$	601,755	$	593,926
Rehabilitation hospital	220,634		231,462
Outpatient rehabilitation	271,940		295,903
Concentra	423,423		456,298
Other	81,795		87,391
Total Company	$	1,599,547	$	1,664,980
Adjusted EBITDA:
Critical illness recovery hospital	$	35,967	$	76,773
Rehabilitation hospital	42,379		47,216
Outpatient rehabilitation	26,596		30,199
Concentra	89,469		93,748
Other	(30,564)		(33,873)
Total Company	$	163,847	$	214,063
Total assets:
Critical illness recovery hospital	$	2,367,490	$	2,507,265
Rehabilitation hospital	1,187,118		1,203,069
Outpatient rehabilitation	1,350,374		1,397,823
Concentra	2,339,940		2,300,632
Other	291,022		290,947
Total Company	$	7,535,944	$	7,699,736
Purchases of property, equipment, and other assets:
Critical illness recovery hospital	$	19,569	$	23,658
Rehabilitation hospital	6,274		8,582
Outpatient rehabilitation	9,414		9,932
Concentra	10,240		14,400
Other	1,348		2,313
Total Company	$	46,845	$	58,885

Schedule of reconciliation of Adjusted EBITDA to income before income taxes

A reconciliation of Adjusted EBITDA to income before income taxes is as follows:

	Three Months Ended March 31, 2022
	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra		Other		Total
	(in thousands)
Adjusted EBITDA	$	35,967	$	42,379	$	26,596	$	89,469	$	(30,564)
Depreciation and amortization	(14,618)		(6,802)		(8,029)		(18,812)		(2,778)
Stock compensation expense	—		—		—		(535)		(8,288)
Income (loss) from operations	$	21,349	$	35,577	$	18,567	$	70,122	$	(41,630)	$	103,985
Equity in earnings of unconsolidated subsidiaries											5,397
Interest expense											(35,514)
Income before income taxes											$	73,868

	Three Months Ended March 31, 2023
	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra		Other		Total
	(in thousands)
Adjusted EBITDA	$	76,773	$	47,216	$	30,199	$	93,748	$	(33,873)
Depreciation and amortization	(16,637)		(6,888)		(8,457)		(18,310)		(2,133)
Stock compensation expense	—		—		—		(178)		(10,003)
Income (loss) from operations	$	60,136	$	40,328	$	21,742	$	75,260	$	(46,009)	$	151,457
Equity in earnings of unconsolidated subsidiaries											8,556
Interest expense											(48,571)
Income before income taxes											$	111,442

XML

Revenue from Contracts with Customers (Tables)

3 Months Ended

Mar. 31, 2023

Revenue from Contract with Customer [Abstract]

Schedule of disaggregation of revenue

The following tables disaggregate the Company’s revenue for the three months ended March 31, 2022 and 2023:

	Three Months Ended March 31, 2022
	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra		Other		Total
	(in thousands)
Patient service revenue:
Medicare	$	218,987	$	103,021	$	41,904	$	177	$	—	$	364,089
Non-Medicare	380,986		107,142		214,113		422,046		—		1,124,287
Total patient services revenues	599,973		210,163		256,017		422,223		—		1,488,376
Other revenue	1,782		10,471		15,923		1,200		81,795		111,171
Total revenue	$	601,755	$	220,634	$	271,940	$	423,423	$	81,795	$	1,599,547

	Three Months Ended March 31, 2023
	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra		Other		Total
	(in thousands)
Patient service revenue:
Medicare	$	229,383	$	110,055	$	45,801	$	243	$	—	$	385,482
Non-Medicare	363,305		109,925		231,985		454,598		—		1,159,813
Total patient services revenues	592,688		219,980		277,786		454,841		—		1,545,295
Other revenue	1,238		11,482		18,117		1,457		87,391		119,685
Total revenue	$	593,926	$	231,462	$	295,903	$	456,298	$	87,391	$	1,664,980

XML

Earnings per Share (Tables)

3 Months Ended

Mar. 31, 2023

Earnings Per Share [Abstract]

Schedule of computation of basic and diluted earnings per share

The following table sets forth the net income attributable to the Company, its common shares outstanding, and its participating securities outstanding.

		Basic and Diluted EPS
		Three Months Ended March 31,
		2022		2023
	(in thousands)
Net income		$	55,926	$	85,257
Less: net income attributable to non-controlling interests		6,809		14,452
Net income attributable to the Company		49,117		70,805
Less: Distributed and undistributed income attributable to participating securities		1,643		2,573
Distributed and undistributed income attributable to common shares		$	47,474	$	68,232

The following tables set forth the computation of EPS under the two-class method:

	Three Months Ended March 31,
	2022					2023
	Net Income Allocation		Shares(1)	Basic and Diluted EPS		Net Income Allocation		Shares(1)	Basic and Diluted EPS
	(in thousands, except for per share amounts)
Common shares	$	47,474	129,010	$	0.37	$	68,232	122,553	$	0.56
Participating securities	1,643		4,464	$	0.37	2,573		4,622	$	0.56
Total Company	$	49,117				$	70,805

_______________________________________________________________________________

(1)    Represents the weighted average share count outstanding during the period.

XML

Accounting Policies (Details) - Interest Rate Cap $ in Billions	Mar. 31, 2023 USD ($)
Derivative [Line Items]
Derivative cap interest rate (as a percent)	1.00%
Notional amount	$ 2.0

XML

Credit Risk Concentrations (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Medicare Receivable | Credit Concentration Risk | Accounts Receivable
Concentration Risk [Line Items]
Percentage of concentration risk	20.00%	19.00%

XML

Redeemable Non-Controlling Interests - Schedule of Redeemable Non-Controlling Interests (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Increase (Decrease) in Temporary Equity [Roll Forward]
Balance, beginning	$ 34,043	$ 39,033
Net income attributable to redeemable non-controlling interests	1,641	1,918
Distributions to redeemable non-controlling interests	(1,900)	(1,198)
Redemption value adjustment on redeemable non-controlling interests	436	1,381
Other	179	536
Balance, ending	$ 34,399	$ 41,670

XML

Variable Interest Entities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022
Variable Interest Entity [Line Items]
Assets	$ 7,699,736	$ 7,665,293	$ 7,535,944
Liabilities	6,246,896	6,274,686
Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Assets	254,100	232,100
Liabilities	82,200	78,800
Obligations payable	$ 178,400	$ 158,300

XML

Leases - Schedule of Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating lease cost
Unrelated Parties	$ 76,632	$ 73,962
Related Parties	1,834	1,809
Total	78,466	75,771
Amortization of right-of-use assets
Unrelated Parties	394	347
Related Parties	0	0
Total	394	347
Interest on lease liabilities
Unrelated Parties	320	340
Related Parties	0	0
Total	320	340
Short-term lease cost
Unrelated Parties	0	35
Related Parties	0	0
Total	0	35
Variable lease cost
Unrelated Parties	15,761	13,655
Related Parties	84	39
Total	15,845	13,694
Sublease income
Unrelated Parties	(1,678)	(1,966)
Related Parties	0	0
Total	(1,678)	(1,966)
Total lease cost
Unrelated Parties	91,429	86,373
Related Parties	1,918	1,848
Total	$ 93,347	$ 88,221

XML

Long-Term Debt and Notes Payable - Components of Long-Term Debt And Notes Payable (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Principal Outstanding	$ 3,879,101	$ 3,878,237
Unamortized Premium (Discount)	16,184	17,179
Unamortized Issuance Costs	(14,553)	(15,854)
Carrying Value	3,880,732	3,879,562
Fair Value	$ 3,832,621	$ 3,767,795
Senior notes | 6.250% senior notes
Debt Instrument [Line Items]
Interest rate of debt (as a percent)	6.25%	6.25%
Principal Outstanding	$ 1,225,000	$ 1,225,000
Unamortized Premium (Discount)	20,065	21,555
Unamortized Issuance Costs	(10,206)	(10,948)
Carrying Value	1,234,859	1,235,607
Fair Value	1,188,250	1,163,689
Term loan
Debt Instrument [Line Items]
Principal Outstanding	2,103,437	2,103,437
Unamortized Premium (Discount)	(3,881)	(4,376)
Unamortized Issuance Costs	(4,230)	(4,771)
Carrying Value	2,095,326	2,094,290
Fair Value	2,095,549	2,056,110
Other debt, including finance leases
Debt Instrument [Line Items]
Principal Outstanding	90,664	104,800
Unamortized Premium (Discount)	0	0
Unamortized Issuance Costs	(117)	(135)
Carrying Value	90,547	104,665
Fair Value	90,547	104,665
Revolving facility | Revolving facility
Debt Instrument [Line Items]
Principal Outstanding	460,000	445,000
Unamortized Premium (Discount)	0	0
Unamortized Issuance Costs	0	0
Carrying Value	460,000	445,000
Fair Value	$ 458,275	$ 443,331

XML

Long-Term Debt and Notes Payable - Principal Maturities Of Long-Term Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
2023	$ 24,685
2024	152,429
2025	2,464,015
2026	1,226,308
2027	823
Thereafter	10,841
Total	$ 3,879,101	$ 3,878,237
Senior notes | 6.250% senior notes
Debt Instrument [Line Items]
Interest rate of debt (as a percent)	6.25%	6.25%
2023	$ 0
2024	0
2025	0
2026	1,225,000
2027	0
Thereafter	0
Total	1,225,000	$ 1,225,000
Revolving facility | Revolving facility
Debt Instrument [Line Items]
2023	0
2024	84,923
2025	375,077
2026	0
2027	0
Thereafter	0
Total	460,000	445,000
Term loan
Debt Instrument [Line Items]
2023	4,757
2024	11,150
2025	2,087,530
2026	0
2027	0
Thereafter	0
Total	2,103,437	2,103,437
Other debt, including finance leases
Debt Instrument [Line Items]
2023	19,928
2024	56,356
2025	1,408
2026	1,308
2027	823
Thereafter	10,841
Total	$ 90,664	$ 104,800

XML

Long-Term Debt and Notes Payable - Narrative (Details) - Revolving facility - Select Medical Corporation - Revolving facility $ in Millions	Feb. 21, 2023 USD ($)
Amendment No. 6 To 2017 Select Credit Facilities
Line of Credit Facility [Line Items]
Borrowing capacity, extended maturity date	$ 530.0
2017 Select Credit Facilities
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 650.0

XML

Interest Rate Cap - Narrative (Details) - Interest Rate Cap $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)
Derivative [Line Items]
Derivative cap interest rate (as a percent)	1.00%
Notional amount	$ 2,000.0
Annual premium (in percent)	0.000916
Annual premium amount	$ 1.8
Estimated pre-tax gain expected to be reclassified in the next twelve months	$ 71.1

XML

Interest Rate Cap - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	$ 1,356,564	$ 1,325,902
Ending balance	1,418,441	1,366,896
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent | Interest Rate Cap
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	88,602	12,282
Gain (loss) on interest rate cap cash flow hedge	(2,696)	39,814
Amounts reclassified from accumulated other comprehensive income	(13,252)	39
Ending balance	$ 72,654	$ 52,135

XML

Interest Rate Cap - Schedule of Reclassification out of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Gains (losses) included in interest expense	$ (48,571)	$ (35,514)
Income tax benefit (expense)	(26,185)	(17,942)
Amounts reclassified from accumulated other comprehensive income	70,805	49,117
Reclassification out of Accumulated Other Comprehensive Income | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent | Interest Rate Cap
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Gains (losses) included in interest expense	17,552	(51)
Income tax benefit (expense)	(4,300)	12
Amounts reclassified from accumulated other comprehensive income	$ 13,252	$ (39)

XML

Fair Value of Financial Instruments - Schedule of Interest Rate Cap (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest rate cap contract, current portion	$ 72,127	$ 74,857
Interest rate cap contract, non-current portion	26,994	45,200
Interest Rate Cap | Fair Value, Inputs, Level 2 | Fair Value, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest rate cap contract, current portion	72,127	74,857
Interest rate cap contract, non-current portion	$ 26,994	$ 45,200

XML

Fair Value of Financial Instruments - Schedule of Long-Term Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	$ 3,832,621	$ 3,767,795
Senior notes | 6.250% senior notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate of debt (as a percent)	6.25%	6.25%
Carrying Value	$ 1,234,859	$ 1,235,607
Fair Value	1,188,250	1,163,689
Senior notes | Fair Value, Inputs, Level 2 | 6.250% senior notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	1,234,859	1,235,607
Fair Value	1,188,250	1,163,689
Revolving facility | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	460,000	445,000
Fair Value	458,275	443,331
Term loan
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	2,095,326	2,094,290
Fair Value	2,095,549	2,056,110
Term loan | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	2,095,326	2,094,290
Fair Value	$ 2,095,549	$ 2,056,110

XML

Segment Information - Selected Financial Data (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Segment Reporting Information [Line Items]
Revenue	$ 1,664,980	$ 1,599,547
Adjusted EBITDA	214,063	163,847
Total assets	7,699,736	7,535,944	$ 7,665,293
Purchases of property, equipment, and other assets	58,885	46,845
Operating Segments | Critical Illness Recovery Hospital
Segment Reporting Information [Line Items]
Revenue	593,926	601,755
Adjusted EBITDA	76,773	35,967
Total assets	2,507,265	2,367,490
Purchases of property, equipment, and other assets	23,658	19,569
Operating Segments | Rehabilitation Hospital
Segment Reporting Information [Line Items]
Revenue	231,462	220,634
Adjusted EBITDA	47,216	42,379
Total assets	1,203,069	1,187,118
Purchases of property, equipment, and other assets	8,582	6,274
Operating Segments | Outpatient Rehabilitation
Segment Reporting Information [Line Items]
Revenue	295,903	271,940
Adjusted EBITDA	30,199	26,596
Total assets	1,397,823	1,350,374
Purchases of property, equipment, and other assets	9,932	9,414
Operating Segments | Concentra
Segment Reporting Information [Line Items]
Revenue	456,298	423,423
Adjusted EBITDA	93,748	89,469
Total assets	2,300,632	2,339,940
Purchases of property, equipment, and other assets	14,400	10,240
Other
Segment Reporting Information [Line Items]
Revenue	87,391	81,795
Adjusted EBITDA	(33,873)	(30,564)
Total assets	290,947	291,022
Purchases of property, equipment, and other assets	$ 2,313	$ 1,348

XML

Segment Information - Reconciliation of Adjusted EBITDA to Income Before Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Segment Reporting Information [Line Items]
Adjusted EBITDA	$ 214,063	$ 163,847
Depreciation and amortization	(52,425)	(51,039)
Income from operations	151,457	103,985
Equity in earnings of unconsolidated subsidiaries	8,556	5,397
Interest expense	(48,571)	(35,514)
Income before income taxes	111,442	73,868
Operating Segments | Critical Illness Recovery Hospital
Segment Reporting Information [Line Items]
Adjusted EBITDA	76,773	35,967
Depreciation and amortization	(16,637)	(14,618)
Stock compensation expense	0	0
Income from operations	60,136	21,349
Operating Segments | Rehabilitation Hospital
Segment Reporting Information [Line Items]
Adjusted EBITDA	47,216	42,379
Depreciation and amortization	(6,888)	(6,802)
Stock compensation expense	0	0
Income from operations	40,328	35,577
Operating Segments | Outpatient Rehabilitation
Segment Reporting Information [Line Items]
Adjusted EBITDA	30,199	26,596
Depreciation and amortization	(8,457)	(8,029)
Stock compensation expense	0	0
Income from operations	21,742	18,567
Operating Segments | Concentra
Segment Reporting Information [Line Items]
Adjusted EBITDA	93,748	89,469
Depreciation and amortization	(18,310)	(18,812)
Stock compensation expense	(178)	(535)
Income from operations	75,260	70,122
Other
Segment Reporting Information [Line Items]
Adjusted EBITDA	(33,873)	(30,564)
Depreciation and amortization	(2,133)	(2,778)
Stock compensation expense	(10,003)	(8,288)
Income from operations	$ (46,009)	$ (41,630)

XML

Revenue from Contracts with Customers (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Total revenue	$ 1,664,980	$ 1,599,547
Total patient services revenues
Disaggregation of Revenue [Line Items]
Total revenue	1,545,295	1,488,376
Medicare
Disaggregation of Revenue [Line Items]
Total revenue	385,482	364,089
Non-Medicare
Disaggregation of Revenue [Line Items]
Total revenue	1,159,813	1,124,287
Other revenue
Disaggregation of Revenue [Line Items]
Total revenue	119,685	111,171
Operating Segments | Critical Illness Recovery Hospital
Disaggregation of Revenue [Line Items]
Total revenue	593,926	601,755
Operating Segments | Critical Illness Recovery Hospital | Total patient services revenues
Disaggregation of Revenue [Line Items]
Total revenue	592,688	599,973
Operating Segments | Critical Illness Recovery Hospital | Medicare
Disaggregation of Revenue [Line Items]
Total revenue	229,383	218,987
Operating Segments | Critical Illness Recovery Hospital | Non-Medicare
Disaggregation of Revenue [Line Items]
Total revenue	363,305	380,986
Operating Segments | Critical Illness Recovery Hospital | Other revenue
Disaggregation of Revenue [Line Items]
Total revenue	1,238	1,782
Operating Segments | Rehabilitation Hospital
Disaggregation of Revenue [Line Items]
Total revenue	231,462	220,634
Operating Segments | Rehabilitation Hospital | Total patient services revenues
Disaggregation of Revenue [Line Items]
Total revenue	219,980	210,163
Operating Segments | Rehabilitation Hospital | Medicare
Disaggregation of Revenue [Line Items]
Total revenue	110,055	103,021
Operating Segments | Rehabilitation Hospital | Non-Medicare
Disaggregation of Revenue [Line Items]
Total revenue	109,925	107,142
Operating Segments | Rehabilitation Hospital | Other revenue
Disaggregation of Revenue [Line Items]
Total revenue	11,482	10,471
Operating Segments | Outpatient Rehabilitation
Disaggregation of Revenue [Line Items]
Total revenue	295,903	271,940
Operating Segments | Outpatient Rehabilitation | Total patient services revenues
Disaggregation of Revenue [Line Items]
Total revenue	277,786	256,017
Operating Segments | Outpatient Rehabilitation | Medicare
Disaggregation of Revenue [Line Items]
Total revenue	45,801	41,904
Operating Segments | Outpatient Rehabilitation | Non-Medicare
Disaggregation of Revenue [Line Items]
Total revenue	231,985	214,113
Operating Segments | Outpatient Rehabilitation | Other revenue
Disaggregation of Revenue [Line Items]
Total revenue	18,117	15,923
Operating Segments | Concentra
Disaggregation of Revenue [Line Items]
Total revenue	456,298	423,423
Operating Segments | Concentra | Total patient services revenues
Disaggregation of Revenue [Line Items]
Total revenue	454,841	422,223
Operating Segments | Concentra | Medicare
Disaggregation of Revenue [Line Items]
Total revenue	243	177
Operating Segments | Concentra | Non-Medicare
Disaggregation of Revenue [Line Items]
Total revenue	454,598	422,046
Operating Segments | Concentra | Other revenue
Disaggregation of Revenue [Line Items]
Total revenue	1,457	1,200
Other
Disaggregation of Revenue [Line Items]
Total revenue	87,391	81,795
Other | Total patient services revenues
Disaggregation of Revenue [Line Items]
Total revenue	0	0
Other | Medicare
Disaggregation of Revenue [Line Items]
Total revenue	0	0
Other | Non-Medicare
Disaggregation of Revenue [Line Items]
Total revenue	0	0
Other | Other revenue
Disaggregation of Revenue [Line Items]
Total revenue	$ 87,391	$ 81,795

XML

Earnings per Share - Narrative (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Earnings Per Share [Abstract]
Contractual dividends paid	$ 0	$ 0

XML

Earnings per Share - Net Income Attributable to the Company, Common Shares Outstanding, and Participating Securities Outstanding (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Earnings Per Share [Abstract]
Net income	$ 85,257	$ 55,926
Less: Net income attributable to non-controlling interests	14,452	6,809
Net income attributable to Select Medical Holdings Corporation	70,805	49,117
Basic EPS
Less: Distributed and undistributed income attributable to participating securities - Basic EPS	2,573	1,643
Distributed and undistributed income attributable to common shares	68,232	47,474
Diluted EPS
Less: Distributed and undistributed income attributable to participating securities - Diluted EPS	2,573	1,643
Distributed and undistributed income attributable to common shares	$ 68,232	$ 47,474

XML

Earnings per Share - Computation of EPS Under the Two-Class Method (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Net Income Allocation
Net income allocated to common shares - basic	$ 68,232	$ 47,474
Participating securities - basic	2,573	1,643
Net income allocated to common shares - diluted	68,232	47,474
Participating securities - diluted	2,573	1,643
Net income attributable to Select Medical Holdings Corporation	$ 70,805	$ 49,117
Weighted average common shares outstanding, basic (in shares)	122,553	129,010
Weighted average common shares outstanding, diluted (in shares)	122,553	129,010
Weighted average participating securities outstanding (in shares)	4,622	4,464
Basic EPS
Basic EPS (in dollars per share)	$ 0.56	$ 0.37
Diluted EPS
Diluted EPS (in dollars per share)	$ 0.56	$ 0.37

XML

Commitments and Contingencies (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)
Professional liability claims | Critical Illness Recovery Hospitals, Rehabilitation Hospitals And Outpatient Rehabilitiation
Commitments and Contingencies
Total annual aggregate limit of insurance coverage	$ 37.0
Professional liability claims | Concentra
Commitments and Contingencies
Total annual aggregate limit of insurance coverage	19.0
Professional liability claims | Joint Venture Operations
Commitments and Contingencies
Total annual aggregate limit of insurance coverage	80.0
Professional liability claims | Joint Venture Operations | Minimum
Commitments and Contingencies
Total annual aggregate limit of insurance coverage	23.0
Professional liability claims | Joint Venture Operations | Maximum
Commitments and Contingencies
Total annual aggregate limit of insurance coverage	33.0
General Liability | Critical Illness Recovery Hospitals, Rehabilitation Hospitals And Outpatient Rehabilitiation
Commitments and Contingencies
Total annual aggregate limit of insurance coverage	40.0
General Liability | Concentra
Commitments and Contingencies
Total annual aggregate limit of insurance coverage	$ 19.0

XML

Subsequent Event (Details)	May 03, 2023 $ / shares
Subsequent Event
Subsequent Event [Line Items]
Cash dividend declared (in dollars per share)	$ 0.125